[Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K and marked with asterisks. The omitted information is (i) not material and (ii) the type that the registrant treats as private or confidential.]
Willowbrook: Group Settlement Term Sheet
Pursuant to this binding short form Term Sheet (“Term Sheet”), the Parties agree to the following terms in full and final resolution of the Covered Claims:
1.Documentation.
a.The parties intend this to be a binding Term Sheet, and that it will become binding once it has been executed by an authorized representative from each member of the PEC, as well as by counsel for Sotera Health Company, Sotera Health LLC and Sterigenics U.S., LLC.
b.An authorized representative from each PEC law firm must sign and agree to the terms reflected in the Term Sheet by no later than Monday, January 9, 2023.
c.The Parties signing below (“Parties”) agree to work in good faith to draft and execute a full settlement agreement in accordance with this Term Sheet (“Settlement Agreement” or “Willowbrook Group Settlement Agreement”). The Settlement Agreement is subject to the approval of all of the Parties. The failure to execute a full Settlement Agreement does not impact the binding effect of this Term Sheet.
d.Settling Defendants (as defined below) expressly deny any and all liability. Nothing in this Term Sheet, including the qualified settlement fund amount, is an admission of any alleged fact, liability or fault, or that the use and/or emission of ethylene oxide by and/or from Sterigenics US’s operations in or around Willowbrook, Illinois has ever caused or created safety hazards or health risks of any sort to the surrounding community.
2.Definitions.
a.The word “Plaintiffs” refers to all persons who are plaintiffs with a Covered Claim as of the date this Term Sheet is signed, and includes any additional persons who have become plaintiffs at the time the Settlement Agreement is signed, but does not include those listed on Appendix C. The list of Plaintiffs covered by this Term Sheet is set forth in Appendix A to this Term Sheet, and will be updated by PEC to include any additional persons who have become plaintiffs at the time the Settlement Agreement is signed.
b.The phrase “Clients with Unfiled Claims” refers to individuals who have retained Plaintiffs’ Counsel in connection with a Covered Claim as of the date this Term Sheet is signed, but who have not filed a lawsuit against any of the Released Parties. “Clients with Unfiled Claims” includes any additional individuals who retain Plaintiffs’ Counsel in connection with a Covered Claim after the signing of the Term Sheet and have not yet filed a lawsuit against any of the Released Parties at the time the Settlement Agreement is signed. The list of Clients with Unfiled Claims is set forth in Appendix B to this Term Sheet, and will be updated by PEC to include any additional “Clients with Unfiled Claims” at the time the Settlement Agreement is signed. PEC will in good faith work to finalize retention by any and all potential clients and supplement Appendices A and B accordingly, by the date the Settlement Agreement is signed.
c.The term “PEC” refers to the Plaintiffs’ Executive Committee, which is composed of the following firms: Salvi, Schostock & Pritchard, PC; Romanucci & Blandon, LLC; Hart McLaughlin & Eldridge, LLC; The Collins Law Firm, PC; Smith LaCien, LLP; Tomasik Kotin Kasserman, LLC and Miner Barnhill & Galland, PC.
d.The term “Non-PEC Firms” refers to any and all law firms representing Eligible Claimants that are not members of the PEC.
e.The phrase “Plaintiffs’ Counsel” refers to the law firms representing Eligible Claimants, including the PEC and Non-PEC Firms; a list of those law firms is set forth in Appendix D to this Term Sheet. PEC have represented that they are negotiating this Term Sheet on behalf of Plaintiffs’ Counsel and each of their clients who is a specific Eligible Claimant and is identified in Appendices A and B.
f.“Sotera Health” refers to Sotera Health Company, Sotera Health Holdings, LLC, Sotera Health LLC, Sotera Health Topco Parent, LP, and Sotera Health GP, LLC.
g.“Sterigenics US” refers to Sterigenics U.S., LLC and all of its predecessor and successor entities.
h.“GTCR” refers to GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C.; all funds associated with GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C., including without limitation GTCR Fund IX/A, L.P., GTCR Fund IX/B, L.P., GTCR Co-Invest III, L.P., GTCR Fund XI/A LP, GTCR Fund XI/CLP, GTCR Partners XI/A&C LP, GTCR Co-Invest XI LP, GTCR Investment XI LLC, GTCR Fund XI/A VCOC, GTCR Fund XI/C VCOC; and the respective affiliates, managers, limited partners, and members of (i) GTCR LLC, GTCR L.L.C., GTCR Golder Rauner II, L.L.C., and (ii) the funds associated with GTCR LLC, GTCR L.L.C., and GTCR Golder Rauner II, L.L.C.
i.“Warburg Pincus” refers to Warburg Pincus LLC and all funds, general partners and management companies associated with or managed by Warburg Pincus LLC or its affiliates, including without limitation Warburg Pincus Private Equity XI, LP, Warburg Pincus Private Equity XI-B, LP, Warburg Pincus Private Equity XI-C, LP, Warburg Pincus XI Partners, LP, WP XI Partners, LP, Warburg Pincus XI, LP, WP Global, LLC, Warburg Pincus Partners I, LP, Warburg Pincus GP LLC, Warburg Pincus (Cayman) XI, LP, Warburg Pincus XI-C, LLC, Warburg Pincus Partners II (Cayman), LP, Warburg Pincus (Bermuda) Private Equity GP Ltd., Warburg Pincus & Co., WP XI, LP, Bull Co-Invest, LP, Warburg Pincus Private XI, LP, Warburg Pincus Partners II, LP, Warburg Pincus Partners II Holdings, LP, Warburg Pincus Partners GP LLC, Warburg Pincus Partners II Holdings (Cayman), LP, WPP II Administrative (Cayman), LLC and their respective affiliates, members, officers, directors, partners, and limited partners.
j.The phrase “Settling Defendants” refers to Sotera Health LLC and Sterigenics U.S., LLC.
k.The phrase “Eligible Claimants” refers to the Plaintiffs and Clients with Unfiled Claims, as reflected on Appendices A and B, as supplemented to add any additional plaintiffs or retained clients.
l.The phrase “Covered Claims” refers to the following categories of claims:
i.All claims, past, present, and future, alleged or that could have been alleged for any injury, harm, or damages, and seeking any form of relief, including money damages, restitution, punitive or exemplary damages, injunctive relief, or any other form of relief, related to or arising from alleged use and/or emissions of ethylene oxide from Sterigenics US’s operations in or around Willowbrook, Illinois (“Willowbrook Claims”), including but not limited to all claims against Sterigenics US as successor to Sterigenics EO, Inc., IBA S&I, Inc., Griffith Micro Science, Inc., Micro-Biotrol, Inc., and Micro-Biotrol Company related to the operations of any of those companies in or around Willowbrook, Illinois; and
ii.All claims, past, present, and future, alleged or that could have been alleged in the Bachoe et al. v. Sotera Health Company, et al. action filed on November 1, 2022 in the Circuit Court of Cook County (Case No. 2022-L- 009825), the Bachoe et al. v. Sotera Health Company, et al. action now pending in the U.S. District Court for the Northern District of Illinois (Case No. 22-cv-06292), and any other actual or potential actions seeking to challenge any transfer of assets to or from Sterigenics U.S., LLC, Sotera Health LLC, or any other Released Parties to any other entity or person.
m.The phrase “Other Facility Claims” refers to claims by any individual or entity relating to any other facility (other than a facility in or around Willowbrook, Illinois) owned or operated by any Released Parties and for which Plaintiffs’ Counsel serves as counsel of record or referral counsel. A list of all Other Facility Claims will be provided to Settling Defendants as Appendix G by no later than January 27th, 2023. PEC represents and warrants that they are not currently pursuing any Other Facility Claims, regardless of whether they are counsel of record or referral counsel, other than those listed on Appendix G.
n.The phrase “Released Parties” refers to Sotera Health, Sterigenics US, Warburg Pincus, GTCR, and all their affiliates, predecessors, successors, direct or indirect parents, direct or indirect subsidiaries, assigns, as well as any current, former, direct or indirect partners, managers, members, shareholders, employees, directors, officers, management companies, incorporators, investors, landlords, tenants, suppliers, service providers, customers, consultants, attorneys, agents, declarants, affiants or other representatives, including without limitation [***]. Released Parties also refers to the Released Parties’ insurers, including without limitation Steadfast Insurance Company/Zurich Insurance Group and National Union/AIG.
o.The phrase “Good Faith Settlement” refers to a settlement per the terms of this Term Sheet that is approved by the Circuit Court of Cook, Illinois, County Law Division, as having been entered into in good faith, pursuant to 740 ILCS 100/2.
3.Establishment of Settlement Program
a.PEC represents and warrants that the lists of Plaintiffs and Clients with Unfiled Claims reflected in Appendices A and B is complete and accurate. PEC represents and warrants that there are 870 Eligible Claimants, as reflected on Appendices A and B. PEC further affirm that they have not been retained by any individuals with Covered Claims other than those identified in Appendices A, B, and C, and PEC are not aware of any other individuals who have filed or plan to file Covered Claims.
b.The Parties will cooperate in establishing a Settlement Program and associated documents that comply in all respects with applicable state Rules of Professional Responsibility regarding aggregate settlements including Illinois Rule of Professional Conduct 1.8(g).
c.By participating in the Settlement Program and obtaining a settlement allocation for Eligible Claimant client(s), a Non-PEC Firm agrees to:
i.the Settlement Program Procedures set forth in Paragraph 4 below, including the requirement to provide information regarding Opt-Outs and any client whose status is uncertain, as if the Non-PEC Firm was a PEC member;
ii.the Confidentiality terms described in Paragraph 10 below, including the agreement not to identify Settling Defendants or Released Parties by name in any marketing communications, including websites, as if the Non-PEC Firm was a PEC member; and
iii.other conditions mutually agreed-upon by the Settling Defendants and PEC.
d.The Parties agree to cooperate in seeking a Court Order that facilitates the administration of the Settlement Program and the Settling Defendants’ evaluation of Opt-Outs, including by requiring Non-PEC Firms to comply with Settlement Program Procedures as a condition of participating in the Settlement Program.
e.The associated documents to be prepared by the Parties will include a release of Covered Claims (“Release”) for execution by individual Eligible Claimants who choose to accept their settlement allocation. Eligible Claimants who accept their settlement allocation and execute the Release will be “Settling Claimants”.
f.In the Release, Settling Claimants shall agree to release and covenant not to sue the Released Parties for all Covered Claims and any claims that are or could have been brought against any Released Parties relating to the Covered Claims or based on the conduct alleged in the litigation relating to any Covered Claims.
i.The Settling Claimants shall further expressly acknowledge and agree to release any rights they may have regarding claims relating to or arising from any Covered Claims that the Settling Claimant does not know or suspect to exist in his or her favor at the time of executing the Release and that, if known by him or her, would have materially affected his or her settlement with the Released Parties. The Settling Claimants expressly and knowingly waive any statutory or judicial provisions, rulings, or mandates to the contrary.
ii.Settling Claimants further agree to release all claims, past, present, and future, alleged or that could have been alleged against insurers who have any of the Released Parties as a Named Insured, including but not limited to Steadfast Insurance Company/Zurich Insurance Group and National Union/AIG, relating to or arising from any Covered Claims. For avoidance of doubt, Released Parties maintain, and do not release, any claims they may have against their insurers.
g.The Release will further require that, if any Settling Claimant settles with any third party against whom claims are not released through this settlement (collectively, “Non-Settling Third Parties”), the Settling Claimant will obtain a release from the Non-Settling Third Party for Released Parties for any claim for indemnity, contribution, or similar theory. If any Settling Claimant obtains a judgment against any Non-Settling Third Party, such Settling Claimant will not execute on any portion of that judgment that the Non-Settling Third Party successfully seeks from Released Parties via a claim for indemnity or contribution or similar claim. Settling Claimants agree to indemnify Released Parties for any claims for indemnity or contribution brought by any Non-Settling Third Parties against Released Parties arising from or relating to Settled Claims.
h.The Settlement Agreement will contain provisions that require all Plaintiffs’ Counsel, subject to the exercise of their independent professional judgment, to recommend participating in the settlement to each of his/her clients.
4.Settlement Program Procedures
a.The Settlement Program shall include a Claims Administrator who will serve in a capacity as determined by the PEC, to include evaluating appropriate documentation and applying a claim valuation formula or matrix to determine each Eligible Claimant’s settlement allocation amount. The Settlement Program shall also include an Administrator of the Qualified Settlement Fund (“QSF”) who will be responsible for distributing the settlement funds to be paid to each Settling Claimant. The QSF Administrator and the Claims Administrator may be the same person.
b.The Claims Administrator and QSF Administrator will be selected by the PEC.
c.Each Eligible Claimant will receive notice of their individual settlement allocation amount along with the other disclosures, including any required by Illinois Rule of Professional Conduct 1.8(g). Within 30 days of receiving all required disclosures along with their individual settlement allocation amount as determined by the Claims Administrator, each Eligible Claimant who chooses to accept their settlement allocation and become a Settling Plaintiff must execute the agreed upon Release (“Opt In Deadline”).
i.PEC can request a 30-day extension of the Opt In Deadline, which will not be unreasonably denied.
d.No later than three (3) days after the Opt In Deadline, PEC will confer with the Claims Administrator to prepare a written list of: (a) Settling Claimants; (b) those Eligible Claimants who have indicated that they have declined to accept their settlement allocation or the terms of the Release (“Opt-Out”); and (c) those Eligible Claimants whose status is unclear (for example, because the relevant Plaintiffs’ Counsel can no longer locate the Claimant or because the Claimant has ceased communicating with the relevant Plaintiffs’ Counsel). The written list shall be provided to the Settling Defendants no later than five (5) days after the Opt In Deadline.
e.The Claims Administrator will retain all executed Releases for the Settling Claimants until it is determined whether the Settling Defendants will be proceeding with the settlement or exercising its option to walk away from and void the settlement due to insufficient participation by the Eligible Claimants. The Claims Administrator must receive an executed Release from the Settling Claimant before any Settlement Funds may be paid to that Settling Claimant.
f.For each Opt-Out, Plaintiffs’ Counsel will complete a Plaintiff Fact Sheet (attached as Appendix E to this Term Sheet) and, to the extent applicable, the Mental Health Addendum (attached as Appendix F to this Term Sheet) and provide it to Settling Defendants within 15 days of the Opt In Deadline.
g.For each Eligible Claimant whose status is unclear as described in Paragraph 4(d) above, Plaintiffs’ Counsel will complete a Plaintiff Fact Sheet and, to the extent applicable, the Mental Health Addendum, to the best of their ability based on information in their possession and provide it to Settling Defendants within 15 days of the Opt In Deadline.
5.Participation.
a.Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement unless 99% of Eligible Claimants represented by the PEC opt into the settlement.
b.Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement unless 95% of the Claimants represented by Non- PEC Firms opt into the settlement.
c.If any Opt-Out fits into one or more of the following categories, then Settling Defendants will have the absolute option to walk away from and void the settlement:
i.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and a cancer injury;
ii.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies) and a breast cancer or hematopoietic cancer injury;
iii.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and more than one miscarriage;
iv.Any Eligible Claimant alleging ethylene oxide exposure at any location (e.g., residences, workplaces, schools, etc.) closer than two miles from the Willowbrook facility (as the crow flies) and any injury to reproductive health besides miscarriage (including, but not limited to, infertility, stillbirth, premature birth, or birth defect);
v.Any Eligible Claimant alleging ethylene oxide exposure between 1984 and 1989 at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies);
vi.Any Eligible Claimant alleging ethylene oxide exposure for 5 years or more at any location (e.g., residences, workplaces, schools, etc.) closer than three miles from the Willowbrook facility (as the crow flies); or
vii.Any Eligible Claimant alleging ethylene oxide exposure for 10 years or more at any location (e.g., residences, workplaces, schools, etc.) closer than four miles from the Willowbrook facility (as the crow flies).
d.After receiving the information described in Paragraph 4(d)-(g) above, Settling Defendants will have 15 days to evaluate the information provided (“Settling Defendants’ Review Period”) and, if applicable, to exercise its walk-away rights described in subsections (a)-(c) above, or elect to proceed with the settlement and waive the requirements of subsections (a)-(c) above. At the expiration of the Settling Defendants’ Review Period, Settling Defendants will notify the PEC and Claims Administrator of their decision whether to proceed with the settlement, if applicable. In the event the participation criteria have been met or, if applicable, Settling Defendants elect to proceed with the settlement (“Settling Defendants’ Decision to Proceed”), the settlement will be binding on all Settling Claimants who accepted their settlement allocation and submitted a Release.
e.Plaintiffs’ Counsel represent and warrant that there are 870 Eligible Claimants, as reflected on Appendices A and B. Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement if it is determined based on the claim formulation or matrix that 40 or more Eligible Claimants do not have valid claims or are otherwise deemed not entitled to any recovery.
f.In addition to the walk-away rights described above in sections 5(a)-(e), Settling Defendants will have the absolute option, in their sole discretion, to walk away from and void the settlement if, before the final funding date for the QSF (as defined below), they learn of more than 5 other Willowbrook claims by Plaintiffs’ Counsel, not listed in Appendix A or B, against any of the Released Parties relating to any Covered Claim(s).
g.Any disagreement or dispute between the parties involving the participation level or percentage participation of claimants described in this Paragraph will be resolved by the parties submitting any such disagreement or dispute to Miles Ruthberg, whose resolution of the dispute will be final.
6.Funding Amount and Procedure.
a.The amount of settlement funds for the Settlement Program will be $285.5 million (“Settlement Funds”).
b.The Parties will establish an escrow account (“Escrow Account”). Settling Defendants will select the institution (“Escrow Agent”) to hold the Escrow Account with PEC’s consent, which will not be unreasonably withheld. The Parties will cooperate to prepare an escrow agreement with instructions to the Escrow Agent consistent with the obligations set forth in this Term Sheet.
c.The Parties will also establish an interest-bearing qualified settlement fund (“QSF”). PEC will select the financial institution to hold the qualified settlement fund with Settling Defendants’ consent, which will not be unreasonably withheld. The QSF shall be treated as being at all times a “qualified settlement fund” for US federal income tax purposes, and the Parties shall act accordingly.
d.Sterigenics U.S., LLC is exclusively responsible for paying the Settlement Funds to the Escrow Account.
e.Sotera Health Company agrees to be guarantor of Sterigenics U.S., LLC’s obligation to pay the Settlement Funds to the Escrow Account until said funds are deposited into the Escrow Account.
f.Sterigenics U.S., LLC will deposit the Settlement Funds in the Escrow Account or transmit the Settlement Funds to the designated Escrow Agent to be deposited into the Escrow Account by or on May 1, 2023, subject to the conditions set forth below in subsection (h).
g.Subject to the conditions set forth in subsection (h), the Escrow Agent will release the Settlement Funds from the Escrow Account to the QSF within 30 days of the final order on appeal affirming the GFSD (as defined below). If there is no appeal of the Court’s GFSD, the Escrow Agent will release the Settlement Funds to the QSF within 7 days of the expiration of the deadline to file an appeal from the Court’s GFSD, subject to the conditions set forth in subsection (h).
h.In the event of the failure of any of the conditions set forth below, the duties set forth in subsections (f) and (g) will be deferred until the conditions have been satisfied:
i.the continued operation of a stay on the actions set forth in Paragraph 8 below;
ii.the absence of any viable lawsuit challenging this Term Sheet or the Settlement Agreement; or
iii.compliance by PEC and Plaintiffs’ Counsel with all material duties and obligations set forth in this Term Sheet, the Settlement Agreement, and otherwise in connection with settlement.
i.In the event the Settling Defendants exercise their walk-away rights under this Term Sheet, or this Term Sheet otherwise becomes void, the duties set forth in subsections (f) and (g) are likewise void. In the event Sterigenics U.S., LLC has already deposited the Settlement Funds into the Escrow Account, those funds will be promptly returned by the Escrow Agent to Sterigenics U.S., LLC.
j.Any disagreement or dispute between the parties involving the conditions or obligations of the Parties described in this Paragraph will be resolved by the Parties submitting any such disagreement or dispute to Miles Ruthberg, whose resolution of the dispute will be final.
k.Fees incurred in connection with the administration of the Settlement Program, including fees of the Claims Administrator and any fees or costs associated with establishing and/or maintaining the QSF, are to be paid by Settling Claimants and/or Plaintiffs’ Counsel from the QSF, consistent with applicable state Rules of Professional Conduct.
l.Settling Defendants and their counsel have played no role in, will play no role in, and will neither take nor bear any responsibility for the allocation of Settlement Funds among the settling plaintiffs or the allocation of settlement funds between settling plaintiffs and Plaintiffs’ Counsel.
m.Sotera Health Company’s agreement to serve as guarantor of Sterigenics U.S., LLC’s obligation to pay the Settlement Funds to the Escrow Account does not constitute an admission of liability or responsibility as a parent company for the actions of Sterigenics U.S., LLC or any other subsidiary with respect to any of the Covered Claims.
7.Good Faith Settlement Determination and Funding
a.Upon satisfaction of the participation criteria set forth in Paragraphs 5(a)-(f), or the Settling Defendants elect to proceed with the settlement notwithstanding any walkaway rights triggered under Paragraphs 5(a)-(f), the parties will promptly file a motion for good-faith settlement determination (“GFSD”) pursuant to 740 ILCS 100/2,including an Ill. S. Ct. R. 304(a) finding.
b.The Parties will use best efforts to obtain a GFSD.
c.If a court does not enter a GFSD, or if the GFSD is overturned on appeal, the parties will return to mediation and use best efforts to resolve any issues.
8.Stay.
a.On January 9, 2023, the Parties will jointly seek a stay of (a) all pending cases related to the Covered Claims of Eligible Claimants listed on Appendices A and B for the purpose of finalizing the Settlement Agreement; and (b) the Bachoe et al. v. Sotera Health Company, et al. action now pending in the U.S. District Court for the Northern District of Illinois (Case No. 22-cv-06292).
b.The Parties will request the stays remain in place until the parties dismiss all pending Eligible Claims pursuant to Paragraph 9 below, or Settling Defendants walk away from the settlement pursuant to Paragraph 5(a)-(f).
c.The Parties’ agreement to the terms reflected in this Term Sheet is contingent on the grant of a stay as described in subsections (a)-(b) above.
d.In the event the Settling Defendants exercise their walk-away rights under this Term Sheet, or this Term Sheet otherwise becomes void, Plaintiffs may seek an immediate lifting of the stay set forth in 8(a).
9.Dismissal.
a.Settling Claimants who submitted a Release will dismiss with prejudice all their pending lawsuits and appeals within 10 days of the date the Escrow Agent releases the Settlement Funds for the Willowbrook Group QSF in Paragraph 6(g).
10.Confidentiality.
a.The Parties agree to maintain confidentiality of the fact of this Term Sheet, any Settlement Agreement, and the terms of such Term Sheet and Settlement Agreement, until the filing of a motion to obtain a stay of litigation. PEC also can discuss the fact, but not amount, of the settlement with Griffith Foods.
b.Eligible Claimants and PEC will not issue any press releases, press briefings, tweets, Instagram posts, or any other social media posts relating to the Term Sheet, any Settlement Agreement, or the terms of the Term Sheet and Settlement Agreement. PEC will not identify Settling Defendants or Released Parties by name in any marketing communications, including websites, but may otherwise discuss information in the public domain.
c.PEC acknowledge that Settling Defendants will be disclosing the principal terms of the overall settlement (including the total amount to be paid by the Settling Defendants) and may also disclose this Term Sheet and the Willowbrook Trial
Plaintiffs’ Term Sheet if the Settling Defendants determine that such disclosure is required by federal securities laws and regulations.
d.The Parties agree that while nothing in this Term Sheet is or will be intended to operate as a restriction on the right of PEC to practice law within the meaning of the relevant states’ equivalent to Rule 5.6(b) of the ABA Model Rules of Professional Conduct in any jurisdiction in which the firm may practice or whose Rules may otherwise apply, PEC represents that they and their respective law firm have no present intention to solicit, accept, or represent new clients for the purpose of bringing any Covered Claim against any Released Party.
e.The Parties agree that while nothing in this Term Sheet is or will be intended to operate as a restriction on the right of PEC to practice law within the meaning of the relevant states’ equivalent to Rule 5.6(b) of the ABA Model Rules of Professional Conduct in any jurisdiction in which the firm may practice or whose Rules may otherwise apply, PEC affirm that, to the best of their knowledge, they have ceased all firm-directed and direct advertising for Covered Claims and have no present intention to resume such advertising. This includes purchases of Google ad words, emails or other communications with client databases regarding Covered Claims and any other solicitation originating from any PEC in any medium, including television, billboards, websites, blogs, internet ads or pop-ups, newspapers, magazines, Facebook, Twitter, Instagram, or other social media outlets.
11.Attorneys’ Fees, Taxes, Liens and Rights of Subrogation.
a.Released Parties have no responsibility whatsoever for the payment of Settling Claimants’ attorneys’ fees or costs, or for the payment of any taxes owed by Settling Claimants, or for satisfaction of liens associated with allocations of funds.
b.Settling Claimants are solely responsible for their respective liens and will indemnify and hold harmless Settling Defendants and all Released Parties from claims by lienholders, actual or asserted.
c.The Parties will establish a process for identifying and resolving liens or subrogation or subrogated claims prior to the funding of the QSF.
d.Settling Claimants agree that any interest in, lien on, or right of subrogation in their Covered Claim by or belonging to any and all entities and individuals, including without limitation any governmental agencies or authorities, attorneys, litigation funders, healthcare providers, and/or insurers, will be satisfied by the Settling Claimant’s allocated payment.
e.Each PEC indemnifies and agrees to hold harmless each Settling Defendant and all Released Parties from any claim of any holder of a lien on PEC, to the extent such lien is applicable exclusively to Plaintiffs’ Counsel and not to any Settling Claimant.
f.Released Parties are not responsible for liens or subrogation claims against settlement payments or the costs and expenses incurred in resolving any such liens or subrogation claims against settlement payments.
12.Heirs.
a.For any wrongful death case, the Settling Claimant shall represent and warrant in their Release that they (a) are authorized to resolve the claim of the deceased Eligible Claimant on behalf of the heirs and estate of the deceased Eligible Claimant, (b) that they will ensure that the further allocation of the settlement funds related to the deceased Eligible Claimant’s claim is handled pursuant to applicable law, and (c) that they will indemnify the Released Parties against any claims related to the allocation of the settlement funds among the heirs and estate. The parties agree that Released Parties are entitled to rely on these representations.
13.The dates for commencing or completing of certain actions with this agreement are goals, and not necessarily deadlines. If a goal date or dates are not met on the precise date as set forth herein, the Parties will work together to adjust the timeline goals in order for the Parties to accomplish their agreed upon desire to complete this settlement.
14.With the exception of the Settling Defendants, and notwithstanding any other provision herein, none of the Released Parties has any obligation to the Settling Claimants, financial or otherwise, under this Term Sheet or otherwise as a result of or in consideration for the Settling Claimants opting into the settlement or for releasing and covenanting not to sue the Released Parties.
15.The Parties shall cooperate with respect to compliance with any required tax reporting, including by using reasonable efforts to provide (or to cause Plaintiffs’ Counsel, Plaintiffs, and Clients to provide) any information or tax forms reasonably requested by the Settling Defendants or the Claims Administrator. No amount of taxes shall be withheld by any person making a payment pursuant to the settlement in accordance with this Term Sheet except to the extent required by applicable law.
16.Governing Law. This Term Sheet shall be governed by and construed in accordance with the law of the State of Illinois without regard to any choice-of-law rules that would require the application of the law of another jurisdiction. Any such proceedings relating to this Term Sheet shall be filed in the Circuit Court of Cook County, Illinois.
17.Electronic Signatures. This Term Sheet and any amendments thereto, to the extent signed and delivered by means of a facsimile machine or electronic scan (including in the form of an Adobe Acrobat PDF file format), shall be treated in all manner and respects as an original agreement and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person.
18.Counterparts. This Term Sheet may be executed in any number of counterparts, each of which shall be an original and all of which shall together constitute one and the same instrument. It shall not be necessary for any counterpart to bear the signature of all Parties. Counsel for any Party shall be authorized to assemble a composite counterpart which shall consist of one copy of each page, except the signature pages, together with multiple counterpart signature pages executed on behalf of every party to this Term Sheet. The composite counterpart may then be used by any Party for all purposes as the complete signed and executed Term Sheet.
[Continued on subsequent page]
Plaintiffs' Executive Committee, on Behalf of
Plaintiffs' Counsel
| | |
| /s/ Antonio Romanucci |
| Antonio Romanucci |
| Romanucci & Blandin, LLC |
| | |
| /s/ Todd A. Smith |
| Todd A. Smith |
| Smith LaCien, LLP |
| | |
| /s/ Daniel M. Kotin |
| Daniel M. Kotin |
| Tomasik Kotin Kasserman, LLC |
| | |
| /s/ Shawn M. Collins |
| Shawn M. Collins |
| The Collins Law Firm, P.C. |
| | |
| /s/ Steven A. Hart |
| Steven A. Hart |
| Hart McLaughlin & Eldridge, LLC |
| | |
| /s/ Scott A. Entin |
| Scott Entin |
| Miner, Barnhill & Galland, P.C. |
| | |
| /s/ Patrick A. Salvi, II |
| Patrick A. Salvi, II |
| Salvi, Schostok & Pritchard P.C. |
Settling Defendants
| | |
| /s/ Matthew J. Klaben |
| Matthew J. Klaben |
| Sotera Health LLC |
| January 9, 2023 |
| | |
| /s/ Matthew J. Klaben |
| Matthew J. Klaben |
| Sterigenics U.S., LLC |
| January 9, 2023 |
As Guarantor
| | |
| /s/ Alexander Dimitrief |
| Alexander Dimitrief |
| Sotera Health Company |
| January 9, 2023 |
Willowbrook: Group Settlement Term Sheet Appendix A
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 1 | [***] | 18‐L‐011004 | Smith Lacien | Breast Cancer | No |
| 2 | [***] | 18‐L‐011252 | RB/HME | Breast Cancer | No |
| 3 | [***] | 19‐L‐009163 | CLF/MBG | Multiple Myeloma | No |
| 4 | [***] | 19‐L‐009167 | Smith Lacien | NHL & Breast | No |
| 5 | [***] | 19‐L‐009167 | Smith Lacien | Schwanoma | No |
| 6 | [***] | 19‐L‐009169 | Smith Lacien | Breast Cancer | No |
| 7 | [***] | 19‐L‐009170 | Salvi, Schostok & Pritchard | Hodgkin's Lymphoma | Hashimotos |
Fertility Issues | No |
| 8 | [***] | 19‐L‐009173 | Salvi, Schostok & Pritchard | Non‐Hodgkins Lymphoma | No |
| 9 | [***] | 19‐L‐009176 | Tomasik Kotin Kasserman | Non‐Hodgkin's Lymphoma | No |
| 10 | [***] | 19‐L‐009177 | Tomasik Kotin Kasserman | Acute Myeloid Leukemia | No |
| 11 | [***] | 19‐L‐009178 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 12 | [***] | 19‐L‐009179 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 13 | [***] | 19‐L‐009181 | RB/HME | Breast Cancer | No |
| 14 | [***] | 19‐L‐009182 | RB/HME | ALL | No |
| 15 | [***] | 19‐L‐009189 | Smith Lacien | Breast cancer | No |
| 16 | [***] | 19‐L‐009190 | CLF/MBG | Mulitple Myeloma | No |
| 17 | [***] | 19‐L‐009196 | RB/HME | AML | No |
| 18 | [***] | 19‐L‐009197 | Wise Morrissey | Pancreatic Cancer | No |
| 19 | [***] | 19‐L‐009198 | RB/HME | Breast Cancer | No |
| 20 | [***] | 19‐L‐009200 | CLF/MBG | Breast Cancer | No |
| 21 | [***] | 19‐L‐009202 | CLF/MBG | Mantle Cell Lymphoma (NHL) | No |
| 22 | [***] | 19‐L‐009205 | CLF/MBG | Miscarriages | No |
| 23 | [***] | 19‐L‐009205 | CLF/MBG | NHL | No |
| 24 | [***] | 19‐L‐009206 | CLF/MBG | Breast Cancer | No |
| 25 | [***] | 19‐L‐009207 | CLF/MBG | Breast Cancer; Miscarriage | No |
| 26 | [***] | 19‐L‐009213 | CLF/MBG | ALL | No |
| 27 | [***] | 19‐L‐009214 | CLF/MBG | Breast Cancer; Miscarriages | No |
| 28 | [***] | 19‐L‐009215 | CLF/MBG | Sezary Syndrome (NHL) | No |
| 29 | [***] | 19‐L‐009216 | CLF/MBG | Breast Cancer | No |
| 30 | [***] | 19‐L‐009362 | Motherway & Napleton | Amyloidosis | No |
| 31 | [***] | 19‐L‐009454 | Motherway & Napleton | Breast Cancer | No |
| 32 | [***] | 19‐L‐009508 | CLF/MBG | ALL | No |
| 33 | [***] | 19‐L‐009528 | Nolan Law | Duodenal Adenocarcinoma | No |
| 34 | [***] | 19‐L‐009732 | Cavanagh Law Group | Follicular lymphoma/AML | No |
| 35 | [***] | 19‐L‐011510 | Motherway & Napleton | Breast Cancer | No |
| 36 | [***] | 19‐L‐011682 | CLO | Breast Cancer | No |
| 37 | [***] | 19‐L‐013486 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 38 | [***] | 19‐L‐013488 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 39 | [***] | 19‐L‐013493 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 40 | [***] | 19‐L‐013517 | CLF/MBG | Breast Cancer/CLL | No |
| 41 | [***] | 19‐L‐013518 | CLF/MBG | Breast Cancer | No |
| 42 | [***] | 19‐L‐013522 | CLF/MBG | Breast Cancer | No |
| 43 | [***] | 19‐L‐013537 | RB/HME | NHL | No |
| 44 | [***] | 19‐L‐013538 | RB/HME | NHL | No |
| 45 | [***] | 19‐L‐013539 | RB/HME | NHL | No |
| 46 | [***] | 19‐L‐013540 | WSOR | ALL | No |
| 47 | [***] | 19‐L‐013541 | RB/HME | MM | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 48 | [***] | 19‐L‐013544 | RB/HME | MM | No |
| 49 | [***] | 19‐L‐013545 | RB/HME | CLL | No |
| 50 | [***] | 19‐L‐013545 | RB/HME | NHL | No |
| 51 | [***] | 19‐L‐013546 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma ‐ Diffuse
Large B‐Cell | No |
| 52 | [***] | 19‐L‐013550 | Salvi, Schostok & Pritchard | Breast Cancer ‐ Bilateral | No |
| 53 | [***] | 19‐L‐013551 | Salvi, Schostok & Pritchard | Lymphoma, Follicular & Large B‐Cell
Lymphoma | No |
| 54 | [***] | 19‐L‐013552 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 55 | [***] | 19‐L‐013554 | WSOR | Breast Cancer | No |
| 56 | [***] | 19‐L‐013562 | RB/HME | ALL | No |
| 57 | [***] | 19‐L‐013568 | WSOR | Large B Cell Lymphoma | No |
| 58 | [***] | 19‐L‐013575 | CLF/MBG | Breast Cancer | No |
| 59 | [***] | 19‐L‐013576 | CLF/MBG | NHL | No |
| 60 | [***] | 19‐L‐013857 | CLF/MBG | NHL | No |
| 61 | [***] | 19‐L‐013860 | CLF/MBG | Breast Cancer | No |
| 62 | [***] | 19‐L‐014265 | CLF/MBG | Waldenstrom’s Macroglobulinemia | No |
| 63 | [***] | 20‐L‐005064 | TPMB | breast cancer | No |
| 64 | [***] | 20‐L‐006260 | KJS | Chronic Myelogenous Leukemia | No |
| 65 | [***] | 20‐L‐007672 | CLO | None ;Breast Cancer; histiocytosis | No |
| 66 | [***] | 20‐L‐007672 | CLO | Histiocytosis | No |
| 67 | [***] | 20‐L‐008669 | RB/HME | MM | No |
| 68 | [***] | 20‐L‐008671 | RB/HME | ALL | No |
| 69 | [***] | 20‐L‐008673 | RB/HME | Breast/Lymphome | No |
| 70 | [***] | 20‐L‐008675 | RB/HME | Breast Cancer | No |
| 71 | [***] | 20‐L‐008676 | RB/HME | Breast Cancer | No |
| 72 | [***] | 20‐L‐008677 | RB/HME | NHL | No |
| 73 | [***] | 20‐L‐008678 | RB/HME | Pancreatic Cancer | No |
| 74 | [***] | 20‐L‐008682 | RB/HME | Miscarriages | No |
| 75 | [***] | 20‐L‐008686 | Tomasik Kotin Kasserman | Breast Cancer and Infertility | No |
| 76 | [***] | 20‐L‐008688 | Tomasik Kotin Kasserman | Breast Cancer and Infertility | No |
| 77 | [***] | 20‐L‐008691 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 78 | [***] | 20‐L‐008692 | Tomasik Kotin Kasserman | Stomach Cancer | No |
| 79 | [***] | 20‐L‐008695 | RB/HME | NHL (Burkett's) | No |
| 80 | [***] | 20‐L‐008699 | RB/HME | Breast cancer; 2 miscarriages;
infertility | No |
| 81 | [***] | 20‐L‐008701 | RB/HME | Breast Cancer | No |
| 82 | [***] | 20‐L‐008702 | RB/HME | Testicular Cancer | No |
| 83 | [***] | 20‐L‐008704 | RB/HME | Follicular Lymphoma | No |
| 84 | [***] | 20‐L‐008705 | RB/HME | Breast Cancer | No |
| 85 | [***] | 20‐L‐008706 | RB/HME | Stomach Cancer | No |
| 86 | [***] | 20‐L‐008708 | RB/HME | Miscarriages | No |
| 87 | [***] | 20‐L‐008709 | RB/HME | Miscarriages | No |
| 88 | [***] | 20‐L‐008715 | RB/HME | Breast Cancer | No |
| 89 | [***] | 20‐L‐008716 | Motherway & Napleton | Breast Cancer | No |
| 90 | [***] | 20‐L‐008718 | Motherway & Napleton | Idiopathic Pulmonary Fibrosis | No |
| 91 | [***] | 20‐L‐008719 | KJS | Breast Cancer | No |
| 92 | [***] | 20‐L‐008720 | RB/HME | Miscarriages | No |
| 93 | [***] | 20‐L‐008721 | KJS | NHL | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 94 | [***] | 20‐L‐008722 | RB/HME | Miscarriages | No |
| 95 | [***] | 20‐L‐008724 | CLF/MBG | Breast Cancer | No |
| 96 | [***] | 20‐L‐008737 | TPMB | pituitary adenoma | No |
| 97 | [***] | 20‐L‐008740 | RB/HME | Breast Cancer | No |
| 98 | [***] | 20‐L‐008741 | RB/HME | Bladder Cancer; Prostate Cancer | No |
| 99 | [***] | 20‐L‐008741 | RB/HME | Miscarriages | No |
| 100 | [***] | 20‐L‐008742 | RB/HME | Breast Cancer | No |
| 101 | [***] | 20‐L‐008743 | RB/HME | NHL | No |
| 102 | [***] | 20‐L‐008745 | RB/HME | ALL | No |
| 103 | [***] | 20‐L‐008746 | RB/HME | Breast Cancer | No |
| 104 | [***] | 20‐L‐008748 | RB/HME | Breast Cancer | No |
| 105 | [***] | 20‐L‐008749 | RB/HME | Breast Cancer | No |
| 106 | [***] | 20‐L‐008750 | RB/HME | Breast Cancer | No |
| 107 | [***] | 20‐L‐008752 | RB/HME | Breast Cancer | No |
| 108 | [***] | 20‐L‐008753 | RB/HME | NHL | No |
| 109 | [***] | 20‐L‐008755 | RB/HME | Breast Cancer | No |
| 110 | [***] | 20‐L‐008756 | RB/HME | Kidney Cancer | No |
| 111 | [***] | 20‐L‐008757 | RB/HME | Breast Cancer | No |
| 112 | [***] | 20‐L‐008758 | RB/HME | Breast Cancer | No |
| 113 | [***] | 20‐L‐008759 | RB/HME | Breast Cancer | No |
| 114 | [***] | 20‐L‐008762 | RB/HME | Breast Cancer | No |
| 115 | [***] | 20‐L‐008764 | RB/HME | HL | No |
| 116 | [***] | 20‐L‐008765 | RB/HME | HL | No |
| 117 | [***] | 20‐L‐008766 | Power Rogers | Breast Cancer | No |
| 118 | [***] | 20‐L‐008766 | Power Rogers | Leukemia | No |
| 119 | [***] | 20‐L‐008769 | RB/HME | Breast Cancer | No |
| 120 | [***] | 20‐L‐008771 | RB/HME | AML/Fertility | No |
| 121 | [***] | 20‐L‐008774 | Corboy & Demetrio | Breast Cancer | No |
| 122 | [***] | 20‐L‐008776 | Salvi, Schostok & Pritchard | Hodgkin's Lymphoma | No |
| 123 | [***] | 20‐L‐008779 | RB/HME | Breast Cancer | No |
| 124 | [***] | 20‐L‐008787 | Power Rogers | NHL | No |
| 125 | [***] | 20‐L‐008791 | Wise Morrissey | Brain Cancer | No |
| 126 | [***] | 20‐L‐008792 | Wise Morrissey | Breast Cancer | No |
| 127 | [***] | 20‐L‐008794 | RB/HME | NHL | No |
| 128 | [***] | 20‐L‐008795 | RB/HME | Kidney Cancer | No |
| 129 | [***] | 20‐L‐008797 | RB/HME | Breast Cancer | No |
| 130 | [***] | 20‐L‐008797 | RB/HME | Lymphoma | No |
| 131 | [***] | 20‐L‐008799 | RB/HME | Lymphoma | No |
| 132 | [***] | 20‐L‐008800 | RB/HME | Breast Cancer | No |
| 133 | [***] | 20‐L‐008803 | RB/HME | Kidney Cancer | No |
| 134 | [***] | 20‐L‐008806 | RB/HME | Breast Cancer | No |
| 135 | [***] | 20‐L‐008809 | RB/HME | Breast Cancer | No |
| 136 | [***] | 20‐L‐008810 | RB/HME | Miscarriages | No |
| 137 | [***] | 20‐L‐008812 | RB/HME | Leukemia | No |
| 138 | [***] | 20‐L‐008816 | Power Rogers | Multiple Myeloma | No |
| 139 | [***] | 20‐L‐008825 | Power Rogers | Breast Cancer | No |
| 140 | [***] | 20‐L‐008826 | Power Rogers | Non Hodgkin's Lymphoma | No |
| 141 | [***] | 20‐L‐008828 | Power Rogers | Non Hodgkin's Lymphoma | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 142 | [***] | 20‐L‐008829 | Power Rogers | Breast Cancer | No |
| 143 | [***] | 20‐L‐008830 | Power Rogers | Leukemia | No |
| 144 | [***] | 20‐L‐008831 | Corboy & Demetrio | Acute Lymphoblastic Leukemia | No |
| 145 | [***] | 20‐L‐008833 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 146 | [***] | 20‐L‐008834 | Power Rogers | Breast Cancer | No |
| 147 | [***] | 20‐L‐008835 | Power Rogers | Breast Cancer | No |
| 148 | [***] | 20‐L‐008838 | Power Rogers | Breast Cancer | No |
| 149 | [***] | 20‐L‐008840 | Power Rogers | Breast Cancer | No |
| 150 | [***] | 20‐L‐008841 | Cavanagh Law Group | Brain tumor/death | No |
| 151 | [***] | 20‐L‐008842 | Power Rogers | Breast Cancer | No |
| 152 | [***] | 20‐L‐008845 | CLF/MBG | Breast Cancer | No |
| 153 | [***] | 20‐L‐008845 | CLF/MBG | Miscrriage | No |
| 154 | [***] | 20‐L‐008847 | Power Rogers | Breast Cancer | No |
| 155 | [***] | 20‐L‐008850 | Power Rogers | Breast Cancer | No |
| 156 | [***] | 20‐L‐008851 | Cavanagh Law Group | Osteosarcoma/death | No |
| 157 | [***] | 20‐L‐008853 | Power Rogers | Multiple Myeloma | No |
| 158 | [***] | 20‐L‐008860 | Power Rogers | Breast Cancer | No |
| 159 | [***] | 20‐L‐008862 | Corboy & Demetrio | Bladder Cancer | No |
| 160 | [***] | 20‐L‐008868 | Smith Lacien | B‐cell Chronic Lymphocytic Leukemia | No |
| 161 | [***] | 20‐L‐008869 | Smith Lacien | Non‐Hodgkin's Lymphoma | No |
| 162 | [***] | 20-L-008870 | Smith Lacien | Hodgkin's Lymphoma Stage 2b | No |
| 163 | [***] | 20‐L‐008871 | Smith Lacien | Follicular Lymphoma; Tonsil Carcinoma | No |
| 164 | [***] | 20‐L‐008872 | Smith Lacien | Blood Cancer; Uterine Cancer;
Myeloproliferative Neoplasim | No |
| 165 | [***] | 20‐L‐008875 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 166 | [***] | 20‐L‐008876 | Salvi, Schostok & Pritchard | Leukemia Lymphocytic, Chronic | No |
| 167 | [***] | 20‐L‐008879 | Salvi, Schostok & Pritchard | Miscarriages (4) | No |
| 168 | [***] | 20‐L‐008880 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 169 | [***] | 20‐L‐008881 | Salvi, Schostok & Pritchard | Leukemia (MDS) | No |
| 170 | [***] | 20‐L‐008882 | Smith Lacien | Breast Cancer | No |
| 171 | [***] | 20‐L‐008883 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 172 | [***] | 20‐L‐008884 | RB/HME | Breast Cancer | No |
| 173 | [***] | 20‐L‐008885 | RB/HME | Miscarriages | No |
| 174 | [***] | 20‐L‐008887 | RB/HME | Myeloid Leukemia | No |
| 175 | [***] | 20‐L‐008889 | Salvi, Schostok & Pritchard | Lymphoma | Myelodysplastic
Syndromes | No |
| 176 | [***] | 20‐L‐008891 | Smith Lacien | Uterine Cancer; Breast Cancer | No |
| 177 | [***] | 20‐L‐008903 | Salvi, Schostok & Pritchard | Leukemia, Chronic Myeloid | No |
| 178 | [***] | 20‐L‐008905 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 179 | [***] | 20‐L‐008909 | Smith Lacien | Breast Cancer | No |
| 180 | [***] | 20‐L‐008911 | Salvi, Schostok & Pritchard | Breast Cancer ‐ Stage 3 triple negative | No |
| 181 | [***] | 20‐L‐008914 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 182 | [***] | 20‐L‐008917 | Salvi, Schostok & Pritchard | Breast Cancer, Stage III | No |
| 183 | [***] | 20‐L‐008919 | Power Rogers | Breast Cancer | No |
| 184 | [***] | 20‐L‐008923 | Smith Lacien | Breast Cancer | No |
| 185 | [***] | 20‐L‐008925 | CLO | Breast Cancer | No |
| 186 | [***] | 20‐L‐008929 | Salvi, Schostok & Pritchard | Lung cancer | No |
| 187 | [***] | 20‐L‐008930 | Salvi, Schostok & Pritchard | Breast cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 188 | [***] | 20‐L‐008932 | CLO | Breast Cancer | No |
| 189 | [***] | 20‐L‐008933 | CLO | Stomach Adenocarcinoma | No |
| 190 | [***] | 20‐L‐008934 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 191 | [***] | 20‐L‐008937 | CLO | Thyroid Cancer | No |
| 192 | [***] | 20‐L‐008943 | WSOR | Breast Cancer | No |
| 193 | [***] | 20‐L‐008945 | Smith Lacien | Breast Cancer; Lung Cancer | No |
| 194 | [***] | 20‐L‐008945 | Smith Lacien | Non‐Hodgkins Lymphoma | No |
| 195 | [***] | 20‐L‐008946 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 196 | [***] | 20‐L‐008948 | WSOR | Breast & Uterine Cancer | No |
| 197 | [***] | 20‐L‐008949 | Salvi, Schostok & Pritchard | Brain & Lung Cancers | No |
| 198 | [***] | 20‐L‐008950 | Salvi, Schostok & Pritchard | Brain tumor | No |
| 199 | [***] | 20‐L‐008951 | Salvi, Schostok & Pritchard | Leukemia ‐ Acute Myeloid | No |
| 200 | [***] | 20‐L‐008952 | WSOR | Bladder Cancer | No |
| 201 | [***] | 20‐L‐008953 | Salvi, Schostok & Pritchard | Lung Cancer (non‐small cell
adenocarcinoma) | No |
| 202 | [***] | 20‐L‐008957 | WSOR | Fybromyoxoid Sarcoma | No |
| 203 | [***] | 20‐L‐008958 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 204 | [***] | 20‐L‐008959 | WSOR | Pancreatic Cancer | No |
| 205 | [***] | 20‐L‐008961 | Salvi, Schostok & Pritchard | Gastrointestinal Cancer (stomach) | No |
| 206 | [***] | 20‐L‐008962 | Salvi, Schostok & Pritchard | Stomach cancer | No |
| 207 | [***] | 20‐L‐008966 | RB/HME | Colon Cancer | No |
| 208 | [***] | 20‐L‐008971 | RB/HME | Miscarriages | No |
| 209 | [***] | 20‐L‐008989 | WSOR | Prostate Cancer | No |
| 210 | [***] | 20‐L‐009000 | WSOR | Prostate Cancer | No |
| 211 | [***] | 20‐L‐009006 | Smith Lacien | Multiple Myeloma | No |
| 212 | [***] | 20‐L‐009012 | CLF/MBG | Multiple Myeloma | No |
| 213 | [***] | 20‐L‐009018 | CLF/MBG | Breast Cancer | No |
| 214 | [***] | 20‐L‐009277 | RB/HME | Cancer | No |
| 215 | [***] | 20‐L‐009296 | CLF/MBG | Breast Cancer | No |
| 216 | [***] | 20‐L‐009380 | CLF/MBG | Hodgkin's Lymphoma | No |
| 217 | [***] | 20‐L‐012228 | CLF/MBG | Breast cancer | No |
| 218 | [***] | 20‐L‐012899 | CLF/MBG | Breast Cancer, Miscarriage | No |
| 219 | [***] | 21‐L_011277 | Smith Lacien | Non‐Hodgkin's Lymphoma | No |
| 220 | [***] | 21‐L‐001619 | McNabola | Uterine/Endometrial | No |
| 221 | [***] | 21‐L‐002646 | Karamanis | Facial Adenoma? | No |
| 222 | [***] | 21‐L‐006899 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 223 | [***] | 21‐L‐008020 | RB/HME | Breast Cancer | No |
| 224 | [***] | 21‐L‐008023 | RB/HME | Breast Cancer | No |
| 225 | [***] | 21‐L‐008035 | RB/HME | Breast Cancer | No |
| 226 | [***] | 21‐L‐008090 | RB/HME | Multiple Myeloma | No |
| 227 | [***] | 21‐L‐008685 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 228 | [***] | 21‐L‐008692 | Salvi, Schostok & Pritchard | Mantle Cell Lymphoma (NHL) | No |
| 229 | [***] | 21‐L‐008696 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 230 | [***] | 21‐L‐008698 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 231 | [***] | 21‐L‐009476 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 232 | [***] | 21‐L‐010808 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 233 | [***] | 21‐L‐011256 | CLF/MBG | Breast Cancer | No |
| 234 | [***] | 21‐L‐011260 | CLF/MBG | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 235 | [***] | 21‐L‐011261 | Smith Lacien | Breast Cancer | No |
| 236 | [***] | 21‐L‐011263 | CLF/MBG | Breast Cancer | No |
| 237 | [***] | 21‐L‐011265 | CLF/MBG | Breast Cancer | No |
| 238 | [***] | 21‐L‐011266 | Smith Lacien | Large Cell B Lymphoma | No |
| 239 | [***] | 21‐L‐011268 | Smith Lacien | T‐Cell Acute Lymphocytic Leukemia | No |
| 240 | [***] | 21‐L‐011269 | Smith Lacien | Non‐Hodgkin's Lymphoma | No |
| 241 | [***] | 21‐L‐011270 | Smith Lacien | Breast Cancer; Fertility Issues | No |
| 242 | [***] | 21‐L‐011273 | CLF/MBG | Breast Cancer | No |
| 243 | [***] | 21‐L‐011274 | Smith Lacien | Leukemia; Celiac Disease; Anemia | No |
| 244 | [***] | 21‐L‐011276 | CLF/MBG | Breast Cancer | No |
| 245 | [***] | 21‐L‐011278 | CLF/MBG | Breast Cancer | No |
| 246 | [***] | 21‐L‐011279 | Smith Lacien | Non‐Hodgkins Lymphoma | No |
| 247 | [***] | 21‐L‐011280 | Smith Lacien | Breast Cancer | No |
| 248 | [***] | 21‐L‐011281 | Smith Lacien | Non‐Hodgkin's Lymphoma; Breast
Cancer | No |
| 249 | [***] | 21‐L‐011283 | Smith Lacien | Mast Cell Leukemia, Advanced
Systemic Mastocytosis, Myelodysplastic Syndrome. | No |
| 250 | [***] | 21‐L‐011284 | Smith Lacien | Non‐Hodgkin's Lymphoma | No |
| 251 | [***] | 21‐L‐011285 | Smith Lacien | Breast Cancer | No |
| 252 | [***] | 21‐L‐011286 | Smith Lacien | Prostate Cancer; Non‐Hodgkins
Lymphoma | No |
| 253 | [***] | 21‐L‐011288 | Smith Lacien | Large Cell B Type Non‐Hodgkin's
Lymphoma | No |
| 254 | [***] | 21‐L‐011290 | Smith Lacien | Breast Cancer | No |
| 255 | [***] | 21‐L‐011292 | Smith Lacien | Breast Cancer | No |
| 256 | [***] | 21‐L‐011293 | CLF/MBG | Hogkin's Lymphoma | No |
| 257 | [***] | 21‐L‐011293 | CLF/MBG | Hogkin's Lymphoma | No |
| 258 | [***] | 21‐L‐011294 | Smith Lacien | Breast Cancer | No |
| 259 | [***] | 21‐L‐011295 | Smith Lacien | Intertility; Breast Cancer | No |
| 260 | [***] | 21‐L‐011298 | Smith Lacien | Breast Cancer | No |
| 261 | [***] | 21‐L‐011299 | Smith Lacien | Breast Cancer | No |
| 262 | [***] | 21‐L‐011300 | CLF/MBG | Breast Cancer | No |
| 263 | [***] | 21‐L‐011301 | Smith Lacien | Larynx Cancer; Lymphoma | No |
| 264 | [***] | 21‐L‐011302 | Smith Lacien | Breast Cancer; Paillary Thyroid
Carcinoma; Basal Cell Carcinoma | No |
| 265 | [***] | 21‐L‐011303 | CLF/MBG | NHL | No |
| 266 | [***] | 21‐L‐011304 | CLF/MBG | Breast Cancer | No |
| 267 | [***] | 21‐L‐011305 | Smith Lacien | Breast Cancer | No |
| 268 | [***] | 21‐L‐011305 | Smith Lacien | Chronic Myelogenous Leukemia | No |
| 269 | [***] | 21‐L‐011306 | CLF/MBG | Breast Cancer | No |
| 270 | [***] | 21‐L‐011306 | CLF/MBG | Breast Cancer | No |
| 271 | [***] | 21‐L‐011308 | CLF/MBG | Stomach Cancer | No |
| 272 | [***] | 21‐L‐011309 | CLF/MBG | Miscarriages | No |
| 273 | [***] | 21‐L‐011313 | CLF/MBG | Carcinoid Tumor | No |
| 274 | [***] | 21‐L‐011313 | CLF/MBG | Myelodysplastic Syndrome | No |
| 275 | [***] | 21‐L‐011317 | CLF/MBG | Breast Cancer | No |
| 276 | [***] | 21‐L‐011318 | Tomasik Kotin Kasserman | Infertility | No |
| 277 | [***] | 21‐L‐011319 | CLF/MBG | Breast Cancer | No |
| 278 | [***] | 21‐L‐011319 | CLF/MBG | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 279 | [***] | 21‐L‐011319 | CLF/MBG | Smouldering Myeloma | No |
| 280 | [***] | 21‐L‐011320 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 281 | [***] | 21‐L‐011322 | CLF/MBG | Breast Cancer | No |
| 282 | [***] | 21‐L‐011323 | Tomasik Kotin Kasserman | Multiple Myelomia | No |
| 283 | [***] | 21‐L‐011324 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 284 | [***] | 21‐L‐011326 | Tomasik Kotin Kasserman | Infertility | No |
| 285 | [***] | 21‐L‐011327 | Tomasik Kotin Kasserman | Leukemia | No |
| 286 | [***] | 21‐L‐011329 | Tomasik Kotin Kasserman | Stomach Cancer | No |
| 287 | [***] | 21‐L‐011330 | RB/HME | Breast Cancer | No |
| 288 | [***] | 21‐L‐011331 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 289 | [***] | 21‐L‐011332 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 290 | [***] | 21‐L‐011333 | Tomasik Kotin Kasserman | Birth Defects | No |
| 291 | [***] | 21‐L‐011333 | Tomasik Kotin Kasserman | Birth Defects | No |
| 292 | [***] | 21‐L‐011333 | Tomasik Kotin Kasserman | Birth Defects | No |
| 293 | [***] | 21‐L‐011333 | Tomasik Kotin Kasserman | Fertility Issues | No |
| 294 | [***] | 21‐L‐011334 | CLF/MBG | Breast Cancer | No |
| 295 | [***] | 21‐L‐011335 | RB/HME | NHL | No |
| 296 | [***] | 21‐L‐011336 | RB/HME | NHL | No |
| 297 | [***] | 21‐L‐011337 | RB/HME | ALL | No |
| 298 | [***] | 21‐L‐011338 | Salvi, Schostok & Pritchard | Neuroblastoma | No |
| 299 | [***] | 21‐L‐011338 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma, Stage II | No |
| 300 | [***] | 21‐L‐011343 | Tomasik Kotin Kasserman | Breast Cancer | No |
| 301 | [***] | 21‐L‐011347 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 302 | [***] | 21‐L‐011348 | CLF/MBG | Breast Cancer | No |
| 303 | [***] | 21‐L‐011349 | Tomasik Kotin Kasserman | Infertility | No |
| 304 | [***] | 21‐L‐011350 | Tomasik Kotin Kasserman | Fertility Issues | No |
| 305 | [***] | 21‐L‐011351 | Tomasik Kotin Kasserman | Bladder Cancer | No |
| 306 | [***] | 21‐L‐011352 | CLF/MBG | Breast Cancer | No |
| 307 | [***] | 21‐L‐011353 | Salvi, Schostok & Pritchard | Breast Cancer X2 | No |
| 308 | [***] | 21‐L‐011354 | CLF/MBG | Breast Cancer | No |
| 309 | [***] | 21‐L‐011355 | CLF/MBG | Breast Cancer | No |
| 310 | [***] | 21‐L‐011356 | Salvi, Schostok & Pritchard | Lymphoma | No |
| 311 | [***] | 21‐L‐011357 | CLF/MBG | Breast Cancer | No |
| 312 | [***] | 21‐L‐011359 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 313 | [***] | 21‐L‐011360 | CLF/MBG | Breast Cancer | No |
| 314 | [***] | 21‐L‐011361 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 315 | [***] | 21‐L‐011363 | CLF/MBG | Breast Cancer, Miscarriages | No |
| 316 | [***] | 21‐L‐011364 | CLF/MBG | Breast Cancer (Paget's Disease) | No |
| 317 | [***] | 21‐L‐011368 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma X2 | No |
| 318 | [***] | 21‐L‐011369 | RB/HME | HL | No |
| 319 | [***] | 21‐L‐011370 | CLF/MBG | Breast Cancer | No |
| 320 | [***] | 21‐L‐011371 | RB/HME | Breast Cancer | No |
| 321 | [***] | 21‐L‐011372 | CLF/MBG | Waldenstrom’s Macroglobulinemia | No |
| 322 | [***] | 21‐L‐011375 | Salvi, Schostok & Pritchard | Breast cancer | 2 Brain Tumors | No |
| 323 | [***] | 21‐L‐011376 | CLF/MBG | Breast Cancer | No |
| 324 | [***] | 21‐L‐011380 | Salvi, Schostok & Pritchard | Leukemia, Lymphocytic | No |
| 325 | [***] | 21‐L‐011381 | CLF/MBG | Breast Cancer, Miscarriage | No |
| 326 | [***] | 21‐L‐011384 | CLF/MBG | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 327 | [***] | 21‐L‐011385 | Salvi, Schostok & Pritchard | Stomach cancer | No |
| 328 | [***] | 21‐L‐011386 | Salvi, Schostok & Pritchard | Breast Cancer x2 | No |
| 329 | [***] | 21‐L‐011388 | CLF/MBG | Breast Cancer, Miscarriages | No |
| 330 | [***] | 21‐L‐011389 | Salvi, Schostok & Pritchard | Breast cancer & 11 Miscarriages | No |
| 331 | [***] | 21‐L‐011391 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 332 | [***] | 21‐L‐011392 | CLF/MBG | Breast Cancer | No |
| 333 | [***] | 21‐L‐011393 | RB/HME | Breast Cancer | No |
| 334 | [***] | 21‐L‐011395 | Salvi, Schostok & Pritchard | Lymphoma, Splenic Marginal Zone B
Cel | No |
| 335 | [***] | 21‐L‐011396 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 336 | [***] | 21‐L‐011397 | CLF/MBG | Breast Cancer | No |
| 337 | [***] | 21‐L‐011399 | RB/HME | Breast Cancer | No |
| 338 | [***] | 21‐L‐011401 | CLF/MBG | Breast Cancer | No |
| 339 | [***] | 21‐L‐011402 | Salvi, Schostok & Pritchard | Breast Cancer | Non‐Hodgkin's
Lymphoma | No |
| 340 | [***] | 21‐L‐011403 | CLF/MBG | Breast Cancer, Miscarriage | No |
| 341 | [***] | 21‐L‐011404 | CLF/MBG | Breast Cancer | No |
| 342 | [***] | 21‐L‐011405 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 343 | [***] | 21‐L‐011406 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 344 | [***] | 21‐L‐011407 | CLF/MBG | Hodgkin's Lymphoma | No |
| 345 | [***] | 21‐L‐011407 | CLF/MBG | Myelodysplastic Syndrome; AML | No |
| 346 | [***] | 21‐L‐011409 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 347 | [***] | 21‐L‐011411 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 348 | [***] | 21‐L‐011412 | Salvi, Schostok & Pritchard | Breast Cancer ‐ Ductal carcinoma in
situ | No |
| 349 | [***] | 21‐L‐011413 | CLF/MBG | Breast Cancer | No |
| 350 | [***] | 21‐L‐011415 | Salvi, Schostok & Pritchard | Breast cancer | | No |
| 351 | [***] | 21‐L‐011416 | CLF/MBG | Follicular Lymphoma; Diffuse Large B‐
Cell Lymphoma | No |
| 352 | [***] | 21‐L‐011417 | Salvi, Schostok & Pritchard | Breast Cancer X2 | No |
| 353 | [***] | 21‐L‐011419 | CLF/MBG | Hodgkin's Lymphoma | No |
| 354 | [***] | 21‐L‐011421 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 355 | [***] | 21‐L‐011423 | Salvi, Schostok & Pritchard | Non‐Hodgkins Lymphoma | No |
| 356 | [***] | 21‐L‐011424 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 357 | [***] | 21‐L‐011425 | CLF/MBG | CML | No |
| 358 | [***] | 21‐L‐011426 | Salvi, Schostok & Pritchard | Hodgkin's Lymphoma, Nodular
Sclerosis | No |
| 359 | [***] | 21‐L‐011429 | CLF/MBG | Breast Cancer | No |
| 360 | [***] | 21‐L‐011431 | Salvi, Schostok & Pritchard | Breast cancer | 3 Miscarriage | No |
| 361 | [***] | 21‐L‐011432 | RB/HME | Breast Cancer | No |
| 362 | [***] | 21‐L‐011433 | RB/HME | PCV | No |
| 363 | [***] | 21‐L‐011434 | CLF/MBG | Breast Cancer | No |
| 364 | [***] | 21‐L‐011435 | RB/HME | PCV | No |
| 365 | [***] | 21‐L‐011436 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 366 | [***] | 21‐L‐011437 | RB/HME | Breast Cancer | No |
| 367 | [***] | 21‐L‐011439 | RB/HME | Breast Cancer | No |
| 368 | [***] | 21‐L‐011440 | CLF/MBG | Breast Cancer | No |
| 369 | [***] | 21‐L‐011440 | CLF/MBG | CML | No |
| 370 | [***] | 21‐L‐011442 | RB/HME | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 371 | [***] | 21‐L‐011443 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 372 | [***] | 21‐L‐011444 | Salvi, Schostok & Pritchard | Hodgkin's lymphoma | No |
| 373 | [***] | 21‐L‐011445 | RB/HME | Breast Cancer | No |
| 374 | [***] | 21‐L‐011447 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 375 | [***] | 21‐L‐011448 | RB/HME | NHL | No |
| 376 | [***] | 21‐L‐011450 | RB/HME | Breast Cancer; Uterine Cancer; Lung
Cancer | No |
| 377 | [***] | 21‐L‐011452 | RB/HME | Breast Cancer | No |
| 378 | [***] | 21‐L‐011453 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 379 | [***] | 21‐L‐011454 | RB/HME | CML | No |
| 380 | [***] | 21‐L‐011455 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 381 | [***] | 21‐L‐011456 | RB/HME | Breast Cancer | No |
| 382 | [***] | 21‐L‐011457 | CLF/MBG | Colon Cancer | No |
| 383 | [***] | 21‐L‐011458 | RB/HME | Breast Cancer | No |
| 384 | [***] | 21‐L‐011459 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 385 | [***] | 21‐L‐011460 | CLF/MBG | Colon Cancer | No |
| 386 | [***] | 21‐L‐011461 | RB/HME | Breast Cancer | No |
| 387 | [***] | 21‐L‐011462 | RB/HME | Breast Cancer | No |
| 388 | [***] | 21‐L‐011463 | CLF/MBG | Breast Cancer | No |
| 389 | [***] | 21‐L‐011465 | RB/HME | Essential Thrombocythemia | No |
| 390 | [***] | 21‐L‐011467 | Salvi, Schostok & Pritchard | Leukemia Myelofibrosis | No |
| 391 | [***] | 21‐L‐011468 | RB/HME | Breast Cancer | No |
| 392 | [***] | 21‐L‐011469 | RB/HME | AML | No |
| 393 | [***] | 21‐L‐011470 | RB/HME | CLL | No |
| 394 | [***] | 21‐L‐011471 | RB/HME | Breast Cancer | No |
| 395 | [***] | 21‐L‐011472 | RB/HME | Breast Cancer | No |
| 396 | [***] | 21‐L‐011473 | Salvi, Schostok & Pritchard | Brain Cancer (Ependymoma) | No |
| 397 | [***] | 21‐L‐011474 | RB/HME | CLL/SLL | No |
| 398 | [***] | 21‐L‐011475 | Salvi, Schostok & Pritchard | Breast Cancer X2 | No |
| 399 | [***] | 21‐L‐011476 | Salvi, Schostok & Pritchard | Brain Cancer | No |
| 400 | [***] | 21‐L‐011477 | RB/HME | Breast Cancer | No |
| 401 | [***] | 21‐L‐011478 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 402 | [***] | 21‐L‐011479 | RB/HME | Lymphoma | No |
| 403 | [***] | 21‐L‐011480 | Salvi, Schostok & Pritchard | Brain Tumor | No |
| 404 | [***] | 21‐L‐011481 | RB/HME | Breast Cancer | No |
| 405 | [***] | 21‐L‐011483 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 406 | [***] | 21‐L‐011484 | Salvi, Schostok & Pritchard | Leukemia, Lymphocytic | No |
| 407 | [***] | 21‐L‐011485 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 408 | [***] | 21‐L‐011486 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 409 | [***] | 21‐L‐011487 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 410 | [***] | 21‐L‐011488 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 411 | [***] | 21‐L‐011490 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 412 | [***] | 21‐L‐011492 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma x2 | No |
| 413 | [***] | 21‐L‐011493 | RB/HME | NHL | No |
| 414 | [***] | 21‐L‐011494 | Salvi, Schostok & Pritchard | Leukemia (Hairy Cell) | No |
| 415 | [***] | 21‐L‐011495 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 416 | [***] | 21‐L‐011496 | RB/HME | Miscarriages | No |
| 417 | [***] | 21‐L‐011498 | RB/HME | Lung Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 418 | [***] | 21‐L‐011499 | RB/HME | Breast Cancer | No |
| 419 | [***] | 21‐L‐011500 | Salvi, Schostok & Pritchard | breast cancer | No |
| 420 | [***] | 21‐L‐011501 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 421 | [***] | 21‐L‐011502 | Salvi, Schostok & Pritchard | Non‐Hodgkins Lymphoma | No |
| 422 | [***] | 21‐L‐011503 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 423 | [***] | 21‐L‐011504 | Salvi, Schostok & Pritchard | Leukemia, Lymphocytic, Chronic | No |
| 424 | [***] | 21‐L‐011506 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 425 | [***] | 21‐L‐011507 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 426 | [***] | 21‐L‐011508 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 427 | [***] | 21‐L‐011509 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 428 | [***] | 21‐L‐011510 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 429 | [***] | 21‐L‐011511 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 430 | [***] | 21‐L‐011512 | RB/HME | Breast Cancer | No |
| 431 | [***] | 21‐L‐011512 | RB/HME | Breast Cancer | No |
| 432 | [***] | 21‐L‐011512 | RB/HME | Kidney Cancer | No |
| 433 | [***] | 21‐L‐011513 | Salvi, Schostok & Pritchard | Hodgkin's Disease | 2 Miscarriages | No |
| 434 | [***] | 21‐L‐011515 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 435 | [***] | 21‐L‐011516 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 436 | [***] | 21‐L‐011517 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 437 | [***] | 21‐L‐011521 | RB/HME | Thyroid Cancer | No |
| 438 | [***] | 21‐L‐011523 | RB/HME | Breast Cancer | No |
| 439 | [***] | 21‐L‐011524 | RB/HME | Breast Cancer | No |
| 440 | [***] | 21‐L‐011528 | RB/HME | Miscarriages | No |
| 441 | [***] | 21‐L‐011529 | RB/HME | Breast Cancer | No |
| 442 | [***] | 21‐L‐011530 | RB/HME | MM | No |
| 443 | [***] | 21‐L‐011531 | RB/HME | Breast Cancer | No |
| 444 | [***] | 21‐L‐011532 | RB/HME | Breast Cancer | No |
| 445 | [***] | 21‐L‐011533 | RB/HME | Breast Cancer | No |
| 446 | [***] | 21‐L‐011534 | RB/HME | Breast Cancer | No |
| 447 | [***] | 21‐L‐011537 | RB/HME | Breast Cancer | No |
| 448 | [***] | 21‐L‐011538 | RB/HME | MM | No |
| 449 | [***] | 21‐L‐011540 | RB/HME | CML | No |
| 450 | [***] | 21‐L‐011541 | Salvi, Schostok & Pritchard | Breast Cancer, Stage IV | No |
| 451 | [***] | 21‐L‐011542 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 452 | [***] | 21‐L‐011544 | RB/HME | Breast Cancer | No |
| 453 | [***] | 21‐L‐011545 | RB/HME | Breast Cancer | No |
| 454 | [***] | 21‐L‐011546 | Salvi, Schostok & Pritchard | Pancreatic Cancer, Mets. Stage IV | No |
| 455 | [***] | 21‐L‐011547 | RB/HME | Kidney Cancer | No |
| 456 | [***] | 21‐L‐011548 | RB/HME | NHL | No |
| 457 | [***] | 21‐L‐011549 | RB/HME | Breast Cancer | No |
| 458 | [***] | 21‐L‐011550 | RB/HME | Breast Cancer | No |
| 459 | [***] | 21‐L‐011551 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 460 | [***] | 21‐L‐011552 | RB/HME | CLL | No |
| 461 | [***] | 21‐L‐011553 | RB/HME | MM | No |
| 462 | [***] | 21‐L‐011554 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 463 | [***] | 21‐L‐011557 | RB/HME | CLL | No |
| 464 | [***] | 21‐L‐011557 | RB/HME | CLL | No |
| 465 | [***] | 21‐L‐011558 | Salvi, Schostok & Pritchard | Non‐Hodgkins Lymphoma | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 466 | [***] | 21‐L‐011559 | RB/HME | NHL | No |
| 467 | [***] | 21‐L‐011560 | RB/HME | Breast Cancer | No |
| 468 | [***] | 21‐L‐011562 | RB/HME | CLL | No |
| 469 | [***] | 21‐L‐011563 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 470 | [***] | 21‐L‐011564 | RB/HME | NHL | No |
| 471 | [***] | 21‐L‐011565 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 472 | [***] | 21‐L‐011566 | RB/HME | NHL | No |
| 473 | [***] | 21‐L‐011567 | RB/HME | NHL | No |
| 474 | [***] | 21‐L‐011568 | RB/HME | Hairy Cell Leukemia | No |
| 475 | [***] | 21‐L‐011571 | Salvi, Schostok & Pritchard | Breast Cancer | Pancreatic Cancer | No |
| 476 | [***] | 21‐L‐011573 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 477 | [***] | 21‐L‐011574 | RB/HME | Breast Cancer | No |
| 478 | [***] | 21‐L‐011575 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 479 | [***] | 21‐L‐011576 | RB/HME | Breast Cancer | No |
| 480 | [***] | 21‐L‐011577 | Salvi, Schostok & Pritchard | Leukemia, Chronic Lymphocytic | No |
| 481 | [***] | 21‐L‐011578 | RB/HME | NHL | No |
| 482 | [***] | 21‐L‐011579 | RB/HME | CLL | No |
| 483 | [***] | 21‐L‐011580 | RB/HME | Breast Cancer | No |
| 484 | [***] | 21‐L‐011581 | RB/HME | NHL | No |
| 485 | [***] | 21‐L‐011582 | RB/HME | MM | No |
| 486 | [***] | 21‐L‐011584 | Salvi, Schostok & Pritchard | Breast Cancer | Lung Cancer | No |
| 487 | [***] | 21‐L‐011585 | RB/HME | Breast Cancer | No |
| 488 | [***] | 21‐L‐011586 | Salvi, Schostok & Pritchard | Leukemia | No |
| 489 | [***] | 21‐L‐011587 | RB/HME | Breast Cancer | No |
| 490 | [***] | 21‐L‐011588 | RB/HME | NHL | No |
| 491 | [***] | 21‐L‐011589 | Salvi, Schostok & Pritchard | Pancreatic Cancer | No |
| 492 | [***] | 21‐L‐011590 | RB/HME | Multiple Myeloma | No |
| 493 | [***] | 21‐L‐011592 | RB/HME | CLL | No |
| 494 | [***] | 21‐L‐011593 | RB/HME | Breast Cancer | No |
| 495 | [***] | 21‐L‐011594 | RB/HME | CMML | No |
| 496 | [***] | 21‐L‐011596 | RB/HME | Breast Cancer | No |
| 497 | [***] | 21‐L‐011597 | RB/HME | Breast Cancer | No |
| 498 | [***] | 21‐L‐011598 | RB/HME | NHL | No |
| 499 | [***] | 21‐L‐011600 | Salvi, Schostok & Pritchard | Lymphoma | No |
| 500 | [***] | 21‐L‐011602 | RB/HME | Breast Cancer | No |
| 501 | [***] | 21‐L‐011603 | RB/HME | MM/Leukemia | No |
| 502 | [***] | 21‐L‐011604 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 503 | [***] | 21‐L‐011605 | RB/HME | Breast Cancer | No |
| 504 | [***] | 21‐L‐011606 | RB/HME | Breast Cancer | No |
| 505 | [***] | 21‐L‐011607 | Salvi, Schostok & Pritchard | Leukemia | No |
| 506 | [***] | 21‐L‐011608 | RB/HME | Breast Cancer | No |
| 507 | [***] | 21‐L‐011609 | Salvi, Schostok & Pritchard | Breast cancer x4 | No |
| 508 | [***] | 21‐L‐011611 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 509 | [***] | 21‐L‐011614 | RB/HME | Breast Cancer | No |
| 510 | [***] | 21‐L‐011615 | Salvi, Schostok & Pritchard | Breast Cancer | Lymphoma | No |
| 511 | [***] | 21‐L‐011616 | RB/HME | AML | No |
| 512 | [***] | 21‐L‐011617 | Salvi, Schostok & Pritchard | Pancreatic Cancer | No |
| 513 | [***] | 21‐L‐011618 | RB/HME | NHL (Waldenstroms) | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 514 | [***] | 21‐L‐011619 | RB/HME | Breast Cancer | No |
| 515 | [***] | 21‐L‐011620 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 516 | [***] | 21‐L‐011621 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 517 | [***] | 21‐L‐011622 | RB/HME | NHL | No |
| 518 | [***] | 21‐L‐011623 | RB/HME | AML | No |
| 519 | [***] | 21‐L‐011624 | Salvi, Schostok & Pritchard | Leukemia | No |
| 520 | [***] | 21‐L‐011625 | RB/HME | Miscarriages | No |
| 521 | [***] | 21‐L‐011626 | Salvi, Schostok & Pritchard | Non Hodgkin's Lymphoma | No |
| 522 | [***] | 21‐L‐011627 | Salvi, Schostok & Pritchard | Lymphoma | No |
| 523 | [***] | 21‐L‐011628 | RB/HME | Breast Cancer | No |
| 524 | [***] | 21‐L‐011629 | RB/HME | HL | No |
| 525 | [***] | 21‐L‐011630 | RB/HME | Leukemia | No |
| 526 | [***] | 21‐L‐011631 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 527 | [***] | 21‐L‐011632 | RB/HME | Miscarriages | No |
| 528 | [***] | 21‐L‐011633 | Salvi, Schostok & Pritchard | Brain, Prostate & Lung Cancers | No |
| 529 | [***] | 21‐L‐011634 | RB/HME | Breast Cancer | No |
| 530 | [***] | 21‐L‐011635 | RB/HME | Breast Cancer | No |
| 531 | [***] | 21‐L‐011636 | Salvi, Schostok & Pritchard | Lung Cancer, Non‐Small Cell | No |
| 532 | [***] | 21‐L‐011637 | RB/HME | Breast Cancer | No |
| 533 | [***] | 21‐L‐011638 | RB/HME | Hodgkin's Lymphoma; prostate
cancer;lymph node | No |
| 534 | [***] | 21‐L‐011639 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 535 | [***] | 21‐L‐011640 | RB/HME | Breast Cancer | No |
| 536 | [***] | 21‐L‐011641 | RB/HME | Birth Defect | No |
| 537 | [***] | 21‐L‐011641 | RB/HME | NHL | No |
| 538 | [***] | 21‐L‐011642 | Salvi, Schostok & Pritchard | Neuroblastoma | No |
| 539 | [***] | 21‐L‐011643 | RB/HME | Fertility | No |
| 540 | [***] | 21‐L‐011644 | RB/HME | CLL | No |
| 541 | [***] | 21‐L‐011645 | RB/HME | Breast Cancer | No |
| 542 | [***] | 21‐L‐011647 | RB/HME | Breast Cancer | No |
| 543 | [***] | 21‐L‐011648 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 544 | [***] | 21‐L‐011649 | RB/HME | Birth Defect | No |
| 545 | [***] | 21‐L‐011650 | RB/HME | Breast Cancer | No |
| 546 | [***] | 21‐L‐011651 | RB/HME | Breast Cancer | No |
| 547 | [***] | 21‐L‐011652 | RB/HME | Miscarriages | No |
| 548 | [***] | 21‐L‐011653 | RB/HME | Miscarriages | No |
| 549 | [***] | 21‐L‐011654 | RB/HME | Breast Cancer | No |
| 550 | [***] | 21‐L‐011655 | RB/HME | Breast Cancer | No |
| 551 | [***] | 21‐L‐011656 | RB/HME | CLL | No |
| 552 | [***] | 21‐L‐011656 | RB/HME | Hairy Cell Leukemia | No |
| 553 | [***] | 21‐L‐011657 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 554 | [***] | 21‐L‐011658 | RB/HME | Testicular Cancer | No |
| 555 | [***] | 21‐L‐011659 | RB/HME | Breast Cancer | No |
| 556 | [***] | 21‐L‐011660 | RB/HME | Breast Cancer | No |
| 557 | [***] | 21‐L‐011661 | RB/HME | Kidney Cancer | No |
| 558 | [***] | 21‐L‐011662 | RB/HME | Breast Cancer | No |
| 559 | [***] | 21‐L‐011663 | RB/HME | Breast Cancer | No |
| 560 | [***] | 21‐L‐011664 | RB/HME | Miscarriages | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 561 | [***] | 21‐L‐011666 | RB/HME | Miscarriages | No |
| 562 | [***] | 21‐L‐011667 | RB/HME | Breast Cancer | No |
| 563 | [***] | 21‐L‐011668 | RB/HME | AML | No |
| 564 | [***] | 21‐L‐011669 | RB/HME | Leukemia | No |
| 565 | [***] | 21‐L‐011671 | RB/HME | Breast Cancer | No |
| 566 | [***] | 21‐L‐011672 | RB/HME | Multiple Myeloma | No |
| 567 | [***] | 21‐L‐011673 | RB/HME | AML | No |
| 568 | [***] | 21‐L‐011674 | RB/HME | Breast Cancer | No |
| 569 | [***] | 21‐L‐011677 | RB/HME | Breast Cancer | No |
| 570 | [***] | 21‐L‐011679 | Salvi, Schostok & Pritchard | Miscarriage (3) | No |
| 571 | [***] | 21‐L‐011682 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 572 | [***] | 21‐L‐011683 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 573 | [***] | 21‐L‐011684 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 574 | [***] | 21‐L‐011685 | Salvi, Schostok & Pritchard | Glioblastoma (Brain Tumor) | No |
| 575 | [***] | 21‐L‐011689 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 576 | [***] | 21‐L‐011690 | RB/HME | Liver Cancer | No |
| 577 | [***] | 21‐L‐011693 | RB/HME | Pancreatic Cancer | No |
| 578 | [***] | 21‐L‐011695 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 579 | [***] | 21‐L‐011696 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 580 | [***] | 21‐L‐011697 | Salvi, Schostok & Pritchard | Lung Cancer & Brain Tumor x2 | No |
| 581 | [***] | 21‐L‐011698 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 582 | [***] | 21‐L‐011699 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 583 | [***] | 21‐L‐011700 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 584 | [***] | 21‐L‐011701 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 585 | [***] | 21‐L‐011702 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 586 | [***] | 21‐L‐011703 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 587 | [***] | 21‐L‐011705 | Salvi, Schostok & Pritchard | Breast, Lymphoma, Non‐Hodgkin's Lymphoma, Spindle Cell & Skin Cancer | No |
| 588 | [***] | 21‐L‐011708 | Salvi, Schostok & Pritchard | Brain Tumor | No |
| 589 | [***] | 21‐L‐011709 | Salvi, Schostok & Pritchard | Multiple Myeloma | No |
| 590 | [***] | 21‐L‐011710 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 591 | [***] | 21‐L‐011711 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma (Follicular) | No |
| 592 | [***] | 21‐L‐011712 | Salvi, Schostok & Pritchard | Pancreatic Cancer | No |
| 593 | [***] | 21‐L‐011713 | Salvi, Schostok & Pritchard | Brain Cancer | No |
| 594 | [***] | 21‐L‐011717 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 595 | [***] | 21‐L‐011721 | Salvi, Schostok & Pritchard | Glioblastoma Multiforme | No |
| 596 | [***] | 21‐L‐011723 | Salvi, Schostok & Pritchard | Leukemia | Breast cancer | No |
| 597 | [***] | 21‐L‐011724 | Salvi, Schostok & Pritchard | Stomach Cancer | No |
| 598 | [***] | 21‐L‐011725 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 599 | [***] | 21‐L‐011727 | Salvi, Schostok & Pritchard | Hodgkin's Lymphoma | No |
| 600 | [***] | 21‐L‐011728 | Salvi, Schostok & Pritchard | Glioblastoma | No |
| 601 | [***] | 21‐L‐011729 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 602 | [***] | 21‐L‐011730 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 603 | [***] | 21‐L‐011731 | Salvi, Schostok & Pritchard | Leukemia, Chronic Lymphatic | No |
| 604 | [***] | 21‐L‐011732 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 605 | [***] | 21‐L‐011733 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 606 | [***] | 21‐L‐011734 | Salvi, Schostok & Pritchard | Pancreatic Cancer | No |
| 607 | [***] | 21‐L‐011735 | Salvi, Schostok & Pritchard | Lung cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 608 | [***] | 21‐L‐011736 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 609 | [***] | 21‐L‐011737 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 610 | [***] | 21‐L‐011738 | Salvi, Schostok & Pritchard | Miscarriages (3) | No |
| 611 | [***] | 21‐L‐011739 | Salvi, Schostok & Pritchard | Breast Cancer ‐ Invasive ductal
carcinoma | No |
| 612 | [***] | 21‐L‐011744 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 613 | [***] | 21‐L‐011745 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 614 | [***] | 21‐L‐011746 | Salvi, Schostok & Pritchard | Lymphoma | No |
| 615 | [***] | 21‐L‐011748 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 616 | [***] | 21‐L‐011749 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 617 | [***] | 21‐L‐011751 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 618 | [***] | 21‐L‐011752 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 619 | [***] | 21‐L‐011754 | Salvi, Schostok & Pritchard | Miscarriages (3) | No |
| 620 | [***] | 21‐L‐011755 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 621 | [***] | 21‐L‐011756 | RB/HME | Miscarriages | No |
| 622 | [***] | 21‐L‐011757 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 623 | [***] | 21‐L‐011758 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 624 | [***] | 21‐L‐011759 | RB/HME | Miscarriages | No |
| 625 | [***] | 21‐L‐011761 | Salvi, Schostok & Pritchard | Lymphoma | No |
| 626 | [***] | 21‐L‐011762 | Salvi, Schostok & Pritchard | Leukemia | No |
| 627 | [***] | 21‐L‐011763 | RB/HME | Breast Cancer | No |
| 628 | [***] | 21‐L‐011765 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 629 | [***] | 21‐L‐011767 | RB/HME | Breast Cancer | No |
| 630 | [***] | 21‐L‐011769 | RB/HME | Leukemia | No |
| 631 | [***] | 21‐L‐011770 | RB/HME | Breast Cancer | No |
| 632 | [***] | 21‐L‐011772 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 633 | [***] | 21‐L‐011774 | RB/HME | Multiple Myeloma | No |
| 634 | [***] | 21‐L‐011775 | RB/HME | CLL | No |
| 635 | [***] | 21‐L‐011777 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 636 | [***] | 21‐L‐011778 | RB/HME | Breast Cancer | No |
| 637 | [***] | 21‐L‐011779 | RB/HME | Miscarriages | No |
| 638 | [***] | 21‐L‐011781 | RB/HME | Birth Defect | No |
| 639 | [***] | 21‐L‐011781 | RB/HME | Birth Defect | No |
| 640 | [***] | 21‐L‐011784 | Salvi, Schostok & Pritchard | Lung Cancer | No |
| 641 | [***] | 21‐L‐011785 | RB/HME | Stomach Cancer | No |
| 642 | [***] | 21‐L‐011786 | RB/HME | Miscarriages | No |
| 643 | [***] | 21‐L‐011787 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 644 | [***] | 21‐L‐011788 | Salvi, Schostok & Pritchard | Leukemia | No |
| 645 | [***] | 21‐L‐011791 | RB/HME | Testicular Cancer | No |
| 646 | [***] | 21‐L‐011792 | RB/HME | Kidney Cancer | No |
| 647 | [***] | 21‐L‐011794 | Salvi, Schostok & Pritchard | Leukemia, Acute | No |
| 648 | [***] | 21‐L‐011795 | RB/HME | Lung Cancer | No |
| 649 | [***] | 21‐L‐011796 | Salvi, Schostok & Pritchard | Lung cancer | No |
| 650 | [***] | 21‐L‐011797 | RB/HME | Miscarriages | No |
| 651 | [***] | 21‐L‐011798 | RB/HME | Miscarriages | No |
| 652 | [***] | 21‐L‐011799 | RB/HME | Breast Cancer | No |
| 653 | [***] | 21‐L‐011801 | RB/HME | Breast Cancer | No |
| 654 | [***] | 21‐L‐011803 | RB/HME | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 655 | [***] | 21‐L‐011805 | RB/HME | NHL | No |
| 656 | [***] | 21‐L‐011807 | Salvi, Schostok & Pritchard | Lung Cancer (Stage IV) | No |
| 657 | [***] | 21‐L‐011810 | Salvi, Schostok & Pritchard | Leukemia | No |
| 658 | [***] | 21‐L‐011811 | RB/HME | Breast Cancer | No |
| 659 | [***] | 21‐L‐011812 | RB/HME | ALL | No |
| 660 | [***] | 21‐L‐011813 | Salvi, Schostok & Pritchard | Glioblastoma Multiforme | No |
| 661 | [***] | 21‐L‐011814 | RB/HME | Breast Cancer | No |
| 662 | [***] | 21‐L‐011815 | Salvi, Schostok & Pritchard | Stomach cancer | No |
| 663 | [***] | 21‐L‐011816 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 664 | [***] | 21‐L‐011817 | RB/HME | Miscarriages | No |
| 665 | [***] | 21‐L‐011819 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 666 | [***] | 21‐L‐011821 | Salvi, Schostok & Pritchard | Glioblastoma (brain tumor) | No |
| 667 | [***] | 21‐L‐011822 | Salvi, Schostok & Pritchard | Lung cancer | No |
| 668 | [***] | 21‐L‐011823 | RB/HME | Breast Cancer | No |
| 669 | [***] | 21‐L‐011823 | RB/HME | Breast Cancer | No |
| 670 | [***] | 21‐L‐011824 | RB/HME | Miscarriages | No |
| 671 | [***] | 21‐L‐011825 | RB/HME | Breast Cancer | No |
| 672 | [***] | 21‐L‐011826 | Salvi, Schostok & Pritchard | Pancreatic Cancer, Thyroid Cancer | No |
| 673 | [***] | 21‐L‐011827 | Salvi, Schostok & Pritchard | Pancreatic & Stage IV Lung Cancers | No |
| 674 | [***] | 21‐L‐011829 | RB/HME | Miscarriages | No |
| 675 | [***] | 21‐L‐011830 | RB/HME | Miscarriages | No |
| 676 | [***] | 21‐L‐011831 | Salvi, Schostok & Pritchard | Breast cancer | No |
| 677 | [***] | 21‐L‐011833 | RB/HME | Leukemia | No |
| 678 | [***] | 21‐L‐011834 | RB/HME | Miscarriages | No |
| 679 | [***] | 21‐L‐011835 | RB/HME | Stomach Cancer | No |
| 680 | [***] | 21‐L‐011836 | Salvi, Schostok & Pritchard | Hodgkin's Lymphoma, Stage 2 | No |
| 681 | [***] | 21‐L‐011838 | RB/HME | Breast Cancer | No |
| 682 | [***] | 21‐L‐011838 | RB/HME | Breast Cancer | No |
| 683 | [***] | 21‐L‐011839 | RB/HME | Breast Cancer | No |
| 684 | [***] | 21‐L‐011840 | Salvi, Schostok & Pritchard | Leukemia ‐ Chronic Myeloid | No |
| 685 | [***] | 21‐L‐011841 | Salvi, Schostok & Pritchard | Breast cancer X2 | No |
| 686 | [***] | 21‐L‐011844 | Salvi, Schostok & Pritchard | Lung cancer | No |
| 687 | [***] | 21‐L‐011846 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 688 | [***] | 21‐L‐011847 | Salvi, Schostok & Pritchard | Lung cancer | No |
| 689 | [***] | 21‐L‐011849 | RB/HME | Breast Cancer | No |
| 690 | [***] | 21‐L‐011851 | Salvi, Schostok & Pritchard | Lung Cancer, Stage III | No |
| 691 | [***] | 21‐L‐011852 | RB/HME | Breast Cancer | No |
| 692 | [***] | 21‐L‐011853 | Salvi, Schostok & Pritchard | Leukemia, Acute myeloid | No |
| 693 | [***] | 21‐L‐011855 | RB/HME | Stomach Cancer | No |
| 694 | [***] | 21‐L‐011856 | Salvi, Schostok & Pritchard | Breast Cancer, Stage IV | No |
| 695 | [***] | 21‐L‐011857 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 696 | [***] | 21‐L‐011858 | RB/HME | Breast Cancer | No |
| 697 | [***] | 21‐L‐011860 | RB/HME | Pancreatic Cancer | No |
| 698 | [***] | 21‐L‐011861 | RB/HME | Breast Cancer | No |
| 699 | [***] | 21‐L‐011862 | RB/HME | Miscarriages | No |
| 700 | [***] | 21‐L‐011863 | Salvi, Schostok & Pritchard | Non‐Hodgkin's Lymphoma | No |
| 701 | [***] | 21‐L‐011864 | RB/HME | Scleroderma | No |
| 702 | [***] | 21‐L‐011865 | RB/HME | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 703 | [***] | 21‐L‐011865 | RB/HME | CLL | No |
| 704 | [***] | 21‐L‐011865 | RB/HME | CLL | No |
| 705 | [***] | 21‐L‐011866 | RB/HME | Fertility | No |
| 706 | [***] | 21‐L‐011867 | RB/HME | Breast Cancer | No |
| 707 | [***] | 21‐L‐011868 | RB/HME | Esophageal Cancer; Rectal Cancer | No |
| 708 | [***] | 21‐L‐011869 | Salvi, Schostok & Pritchard | Leukemia, acute myeloid | No |
| 709 | [***] | 21‐L‐011870 | RB/HME | Breast Cancer | No |
| 710 | [***] | 21‐L‐011871 | Salvi, Schostok & Pritchard | Brain cancer | No |
| 711 | [***] | 21‐L‐011872 | RB/HME | Pancreatic Cancer | No |
| 712 | [***] | 21‐L‐011873 | RB/HME | Breast Cancer | No |
| 713 | [***] | 21‐L‐011874 | RB/HME | Breast Cancer | No |
| 714 | [***] | 21‐L‐011875 | RB/HME | Breast Cancer | No |
| 715 | [***] | 21‐L‐011876 | RB/HME | Follicular Lymphoma | No |
| 716 | [***] | 21‐L‐011877 | Salvi, Schostok & Pritchard | Prostate Cancer | No |
| 717 | [***] | 21‐L‐011881 | RB/HME | Miscarriages | No |
| 718 | [***] | 21‐L‐011882 | RB/HME | Breast Cancer | No |
| 719 | [***] | 21‐L‐011883 | RB/HME | Stomach Cancer | No |
| 720 | [***] | 21‐L‐011885 | RB/HME | Stomach Cancer | No |
| 721 | [***] | 21‐L‐011886 | RB/HME | Breast Cancer | No |
| 722 | [***] | 21‐L‐011887 | RB/HME | HL | No |
| 723 | [***] | 21‐L‐011891 | RB/HME | Miscarriages | No |
| 724 | [***] | 21‐L‐011894 | RB/HME | Breast Cancer | No |
| 725 | [***] | 21‐L‐011896 | RB/HME | Miscarriages | No |
| 726 | [***] | 21‐L‐011898 | RB/HME | Breast Cancer | No |
| 727 | [***] | 21‐L‐011900 | RB/HME | Breast Cancer | No |
| 728 | [***] | 21‐L‐011903 | RB/HME | Miscarriages | No |
| 729 | [***] | 21‐L‐011904 | RB/HME | Miscarriages | No |
| 730 | [***] | 21‐L‐011908 | RB/HME | Breast Cancer | No |
| 731 | [***] | 21‐L‐011909 | RB/HME | Miscarriages | No |
| 732 | [***] | 21‐L‐011911 | RB/HME | Breast Cancer | No |
| 733 | [***] | 21‐L‐011912 | RB/HME | Miscarriages | No |
| 734 | [***] | 21‐L‐011913 | RB/HME | Miscarriages | No |
| 735 | [***] | 21‐L‐011915 | RB/HME | Breast Cancer | No |
| 736 | [***] | 21‐L‐011916 | RB/HME | Birth Defect | No |
| 737 | [***] | 21‐L‐011918 | RB/HME | Breast Cancer | No |
| 738 | [***] | 21‐L‐011919 | RB/HME | Birth Defect | No |
| 739 | [***] | 21‐L‐011920 | RB/HME | NHL | No |
| 740 | [***] | 21‐L‐011921 | RB/HME | Kidney Cancer | No |
| 741 | [***] | 21‐L‐011922 | RB/HME | Kidney Cancer | No |
| 742 | [***] | 21‐L‐011923 | RB/HME | Breast Cancer | No |
| 743 | [***] | 21‐L‐011924 | RB/HME | Miscarriages | No |
| 744 | [***] | 21‐L‐011925 | RB/HME | Testicular Cancer | No |
| 745 | [***] | 21‐L‐011926 | RB/HME | NHL | No |
| 746 | [***] | 21‐L‐011927 | RB/HME | Miscarriages | No |
| 747 | [***] | 21‐L‐011928 | RB/HME | MS; MC | No |
| 748 | [***] | 21‐L‐011944 | RB/HME | Breast Cancer | No |
| 749 | [***] | 21‐L‐011959 | RB/HME | Pancreatic Cancer | No |
| 750 | [***] | 21‐L‐011983 | Corboy & Demetrio | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 751 | [***] | 21‐L‐011994 | Corboy & Demetrio | Breast Cancer | No |
| 752 | [***] | 21‐L‐012003 | Corboy & Demetrio | Breast cancer ‐ DCIS ductal carcinoma | No |
| 753 | [***] | 21‐L‐012006 | Corboy & Demetrio | Papillary thyroid cancer | No |
| 754 | [***] | 21‐L‐012006 | Corboy & Demetrio | Papillary thyroid cancer | No |
| 755 | [***] | 21‐L‐012007 | Corboy & Demetrio | Birth injury bi‐lateral cleft lip and
palate | No |
| 756 | [***] | 21‐L‐012008 | Corboy & Demetrio | Polycythemia Vera | No |
| 757 | [***] | 21‐L‐012678 | Salvi, Schostok & Pritchard | Myeloma | No |
| 758 | [***] | 21‐L‐012714 | Salvi, Schostok & Pritchard | Breast Cancer | No |
| 759 | [***] | 21‐L‐012716 | Salvi, Schostok & Pritchard | NHL | No |
| 760 | [***] | 21‐L‐012932 | RB/HME | AML | No |
| 761 | [***] | 21‐L‐012934 | RB/HME | Breast Cancer | No |
| 762 | [***] | 22‐L‐000298 | Salvi, Schostok & Pritchard | ALL | No |
| 763 | [***] | 22‐L‐001179 | RB/HME | AML | No |
| 764 | [***] | 22‐L‐001180 | RB/HME | Breast Cancer | No |
| 765 | [***] | 22‐L‐001181 | RB/HME | NHL | No |
| 766 | [***] | 22‐L‐001446 | RB/HME | Breast Cancer | No |
| 767 | [***] | 22‐L‐001988 | CLF/MBG | Myeloma | No |
| 768 | [***] | 22‐L‐001996 | RB/HME | Multiple Myeloma | No |
| 769 | [***] | 22‐L‐002835 | RB/HME | Breast Cancer | No |
| 770 | [***] | 22‐L‐002842 | RB/HME | Breast Cancer | No |
| 771 | [***] | 22‐L‐002846 | RB/HME | Breast Cancer | No |
| 772 | [***] | 22‐L‐002847 | RB/HME | Breast Cancer | No |
| 773 | [***] | 22‐L‐002852 | RB/HME | Breast Cancer | No |
| 774 | [***] | 22‐L‐002853 | RB/HME | AML | No |
| 775 | [***] | 22‐L‐002854 | RB/HME | Pancreatic Cancer | No |
| 776 | [***] | 22‐L‐002855 | RB/HME | Breast Cancer | No |
| 777 | [***] | 22‐L‐003036 | SSP | Glioblastoma | No |
| 778 | [***] | 22‐L‐003042 | SSP | Breast Cancer | No |
| 779 | [***] | 22‐L‐003044 | SSP | Breast Cancer | No |
| 780 | [***] | 22‐L‐003046 | SSP | MGUS | No |
| 781 | [***] | 22‐L‐003177 | PR | Breast Cancer | No |
| 782 | [***] | 22‐L‐003186 | PR | NHL | No |
| 783 | [***] | 22‐L‐003187 | PR | Breast/NHL | No |
| 784 | [***] | 22‐L‐004720 | RB/HME | PCV/CLL | No |
| 785 | [***] | 22‐L‐004755 | RB/HME | Breast Cancer | No |
| 786 | [***] | 22‐L‐006970 | RB/HME | Kidney Cancer | No |
| 787 | [***] | 22‐L‐006973 | RB/HME | Breast Cancer | No |
| 788 | [***] | 22‐L‐006974 | RB/HME | Breast Cancer | No |
| 789 | [***] | 22‐L‐006980 | RB/HME | Breast Cancer | No |
| 790 | [***] | 22‐L‐006982 | RB/HME | Breast Cancer | No |
| 791 | [***] | 22‐L‐006985 | RB/HME | Multiple Myeloma | No |
| 792 | [***] | 22‐L‐006989 | RB/HME | Breast Cancer | No |
| 793 | [***] | 22‐L‐006991 | RB/HME | Breast Cancer | No |
| 794 | [***] | 22‐L‐006992 | RB/HME | Breast Cancer | No |
| 795 | [***] | 22‐L‐006993 | RB/HME | Breast Cancer | No |
| 796 | [***] | 22‐L‐006995 | RB/HME | AML | No |
| 797 | [***] | 22‐L‐007002 | RB/HME | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 798 | [***] | 22‐L‐008438 | RB/HME | CLL | No |
| 799 | [***] | 22‐L‐008445 | RB/HME | NHL | No |
| 800 | [***] | 22-L-008794 | TKK | Breast Cancer | No |
| 801 | [***] | 22‐L‐009082 | CLF/MBG | Breast Cancer | No |
| 802 | [***] | 22‐L‐009098 | RB/HME | NHL | No |
| 803 | [***] | 22‐L‐009103 | RB/HME | Breast Cancer | No |
| 804 | [***] | 22‐L‐009110 | RB/HME | Breast Cancer | No |
| 805 | [***] | 22‐L‐009112 | RB/HME | Breast Cancer | No |
| 806 | [***] | 22‐L‐009113 | RB/HME | Breast Cancer | No |
| 807 | [***] | 22‐L‐009115 | RB/HME | Breast Cancer | No |
| 808 | [***] | 22‐L‐009116 | RB/HME | Breast Cancer | No |
| 809 | [***] | 22‐L‐009117 | RB/HME | Breast Cancer | No |
| 810 | [***] | 22‐L‐009118 | RB/HME | Breast Cancer | No |
| 811 | [***] | 22‐L‐009119 | RB/HME | Breast Cancer | No |
| 812 | [***] | 22‐L‐009121 | RB/HME | Lymphoma | No |
| 813 | [***] | 22‐L‐009122 | RB/HME | NHL | No |
| 814 | [***] | 22‐L‐009183 | CLF/MBG | NHL | No |
| 815 | [***] | 22‐L‐009193 | CLF/MBG | Thyroid Cancer | No |
| 816 | [***] | 22‐L‐009345 | RB/HME | Breast Cancer | No |
| 817 | [***] | 22‐L‐009346 | RB/HME | Breast Cancer | No |
| 818 | [***] | 22‐L‐009347 | RB/HME | Breast Cancer | No |
| 819 | [***] | 22‐L‐009348 | RB/HME | Leukemia | No |
| 820 | [***] | 22‐L‐009356 | RB/HME | Breast Cancer | No |
| 821 | [***] | 22‐L‐009409 | Corboy & Demetrio | Pancreatic Cancer | No |
| 822 | [***] | 22-L-009500 | TKK | Neuroendocrine Cancer | No |
| 823 | [***] | 22-L-009500 | TKK | Pancreatic Cancer | No |
| 824 | [***] | 22‐L‐009549 | RB/HME | Breast Cancer | No |
| 825 | [***] | 22‐L‐009552 | RB/HME | Breast Cancer | No |
| 826 | [***] | 22‐L‐009553 | RB/HME | Breast Cancer | No |
| 827 | [***] | 22‐L‐009554 | RB/HME | AML | No |
| 828 | [***] | 22‐L‐009683 | CLF/MBG | Colon Cancer | No |
| 829 | [***] | 22‐L‐011116 | CLF/MBG | Follicular Lymphoma; thyroid cancer;
breast cancer; DLBCL | No |
| 830 | [***] | 22‐L‐011144 | RB/HME | Breast Cancer | No |
| 831 | [***] | 22‐L‐011148 | RB/HME | NHL | No |
| 832 | [***] | 22‐L‐011164 | RB/HME | Hairy Cell Leukemia | No |
| 833 | [***] | 22‐L‐011165 | RB/HME | Breast Cancer | No |
| 834 | [***] | 22‐L‐011211 | RB/HME | Myeloma | No |
| 835 | [***] | 22-L-011253 | TKK | Breast Cancer | No |
| 836 | [***] | 22‐L‐011408 | KJS | Esophageal Cancer | No |
| 837 | [***] | 22‐L‐011409 | KJS | Breast Cancer | No |
| 838 | [***] | 22‐L‐011410 | KJS | Colon Cancer | No |
| 839 | [***] | 22‐L‐011428 | KJS | Breast Cancer | No |
| 840 | [***] | 22‐L‐011479 | SSP | PCV | No |
| 841 | [***] | 22‐L‐011480 | SSP | Breast Cancer | No |
| 842 | [***] | 22‐L‐011481 | SSP | Neuroendocrine Tumor/GIST | No |
| 843 | [***] | 22‐L‐011483 | SSP | HL | No |
| 844 | [***] | 22‐L‐011485 | SSP | Breast Cancer | No |
| | | | | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** | Filed After 1/19 |
| 845 | [***] | 23‐L‐000031 | CLF/MBG | Endometrial Cancer | No |
| 846 | [***] | 23‐L‐000114 | RB/HME | Breast Cancer | No |
| 847 | [***] | 23‐L‐000548 | RB/HME | Breast Cancer | Yes |
Willowbrook: Group Settlement Term Sheet Appendix B
| | | | | | | | | | | | | | |
| CLAIMANT NAME(S) | NEW CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES** |
| 1 | [***] | UNFILED | Smith Lacien | HL |
| 2 | [***] | UNFILED | Smith Lacien | Breast Cancer |
| 3 | [***] | UNFILED | Smith Lacien | Breast Cancer |
| 4 | [***] | UNFILED | Smith Lacien | Multiple Myeloma |
| 5 | [***] | UNFILED | Cavanagh Law Group | Lymphoma |
| 6 | [***] | UNFILED | RB/HME | Breast Cancer |
| 7 | [***] | UNFILED | SSP | Glioblastoma |
| 8 | [***] | UNFILED | SSP | NHL |
| 9 | [***] | UNFILED | SSP | Breast Cancer |
| 10 | [***] | UNFILED | SSP | Lung Cancer |
| 11 | [***] | UNFILED | MN | Myeloproliferative Neoplasm |
| 12 | [***] | UNFILED | MN | Stomach Cancer |
| 13 | [***] | UNFILED | PR | Breast Cancer |
| 14 | [***] | UNFILED | PR | CLL |
| 15 | [***] | UNFILED | PR | Breast Cancer |
| 16 | [***] | UNFILED | PR | Breast Cancer |
| 17 | [***] | UNFILED | PR | Breast Cancer |
| 18 | [***] | UNFILED | PR | Breast Cancer |
| 19 | [***] | UNFILED | PR | Breast Cancer |
| 20 | [***] | UNFILED | WSOR | Breast Cancer |
| 21 | [***] | UNFILED | WSOR | Breast Cancer |
| 22 | [***] | UNFILED | KJS | Uterine Cancer |
| 23 | [***] | UNFILED | PR | Colon Cancer |
| 24 | [***] | UNFILED | PR | NHL |
| 25 | [***] | UNFILED | SSP | Malt Lymphoma |
| 26 | [***] | UNFILED | MN | Brain Cancer |
| 27 | [***] | UNFILED | PR | Breast Cancer |
Willowbrook: Group Settlement Term Sheet Appendix C
| | | | | | | | | | | |
| CLAIMANT NAME(S) | CASE NUMBER | FIRM | DIAGNOSIS/DIAGNOSES |
| Susan Kamuda | 18‐L‐010475 | Salvi, Schostok & Pritchard | Breast Cancer |
| Brian Kamuda | 18‐L‐010475 | Salvi, Schostok & Pritchard | Follicular Lymphoma; Diffuse Large B‐Cell Lymphoma |
| Teresa Fornek | 18‐L‐010744 | Smith Lacien | ALL |
| Doug Fornek | N/A | Smith Lacien | |
| Heather Schumacher and Michael Schumacher |
18‐L‐011939 |
RB/HME |
Hodgkin's Lymphoma |
Willowbrook: Group Settlement Term Sheet Appendix D
| | | | | |
| LAW FIRM NAME |
| 1 | BARNEY & KARAMANIS |
| 2 | CAVANAGH LAW GROUP |
| 3 | THE COLLINS LAW FIRM |
| 4 | CLIFFORD LAW OFFICES |
| 5 | CORBOY & DEMETRIO |
| 6 | DOLAN LAW |
| 7 | EDELSON P.C. |
| 8 | GOLDBERG WEISMAN & CAIRO |
| 9 | HART MCLAUGHLIN & ELDRIDGE |
| 10 | KRALOVEC JAMBOIS & SCHWARTZ |
| 11 | MCNABOLA LAW GROUP |
| 12 | MINER BARNHILL & GALLAND |
| 13 | MOTHERWAY & NAPLETON |
| 14 | NOLAN LAW GROUP |
| 15 | POWER ROGERS |
| 16 | ROMANUCCI & BLANDIN |
| 17 | SALVI SCHOSTOK & PRITCHARD |
| 18 | SMITH LACIEN |
| 19 | TAXMAN POLLACK MURRAY & BEKKERMAN |
| 20 | TOMASIK KOTIN KASSERMAN |
| 21 | WINTERS SALZETTA O'BRIEN & RICHARDSON |
| 22 | WISE MORRISSEY |
Willowbrook: Group Settlement Term Sheet Appendix E
INSTRUCTIONS: If your response to any question in this Settlement Plaintiff Fact Sheet exceeds the space limitation provided in these fillable PDF forms, you must attach additional pages labeling said pages as an Attachment to the respective document and identify the question to which the additional information applies to.
IN THE CIRCUIT COURT OF COOK COUNTY, ILLINOIS COUNTY DEPARTMENT, LAW DIVISION
| | | | | |
| IN RE: WILLOWBROOK ETHYLENE OXIDE LITIGATION | Consolidated for Pretrial and Discovery Purposes Under No. 18 L 10475 |
APPENDIX E
SETTLEMENT PLAINTIFF FACT SHEET
This Settlement Plaintiff Fact Sheet must be completed by or on behalf of each Opt- Out, as defined in the Willowbrook Group Binding Term Sheet (“Term Sheet”)1. Please answer every question to the best of your knowledge. In completing this Settlement Plaintiff Fact Sheet, you are under oath and must provide information that is true and correct to the best of your knowledge as if answering under Illinois law. If you cannot recall all details requested, please provide as much information as you can. Please do not leave any questions unanswered or blank, and attach additional pages if you need more space to answer any of the questions associated with this Settlement Plaintiff Fact Sheet.
Information provided will only be used for purposes related to settlement evaluation and may be disclosed only as permitted by the Stipulation and Order Governing the Protection and Exchange of Confidential Information in the litigation.2
______________________________________
1 “Opt-Out” means an Eligible Claimant who has declined to accept his or her settlement allocation or the terms of the Release, as described in the Term Sheet.
2 In the event the Opt Out chooses to continue to litigate his or her case, the submission of this Settlement Plaintiff Fact Sheet does not satisfy or discharge his or her obligation to prepare a Plaintiff Fact Sheet for the litigation as
required under court orders or discovery rules.
I.CASE INFORMATION
1.Name of person on whose behalf this Settlement Plaintiff Fact Sheet is being prepared (first, middle, last):
2.Name of person completing this form:
3.Please state the following for the civil action filed by the Opt-Out, if any:
a.Case caption:
b.Docket number:
c.Contact information of principal attorney representing the Opt-Out:
Name:
Firm:
Address:
Telephone Number:
Fax Number:
E-mail Address:
4.If you are completing this document in a derivative capacity (e.g., you filed a loss of consortium claim derived from injuries suffered by a family member), please provide the name of the allegedly injured family member(s):
5.If you are completing this document in a representative capacity (e.g., as a legal guardian, or on behalf of the estate of a deceased person), please complete the following:
a.Your name, including other names you have used or by which you have been known and dates you used those names:
b.Current address
c.In what capacity you are representing the individual or estate:
d.If you were appointed as a representative by a court, state the: Court that appointed you_____________________; Date of appointment______________________
e.What is your relationship to the individual you represent:
f.If you represent a decedent’s estate, please state the date and cause of decedent’s death:
II.PERSONAL INFORMATION
1.Opt-Out’s Name:
Other names by which Opt-Out has been known (from prior marriages or otherwise, if any):
2.Sex:
3.Race:
4.Social Security Number:
5.Driver’s license number and state issuing license (if you have had driver’s licenses
6.in more than one state, list response for each state):
7.Date and Place of Birth (City, State, Country):
“YOU” AND “YOUR” REFERENCED IN SECTIONS III-VI OF THIS PLAINTIFF FACT SHEET REQUEST INFORMATION ABOUT THE OPT-OUT, OR, IF THE OPT OUT IS SOMEONE BRINGING A CLAIM IN A REPRESENTATIVE OR DERIVATIVE CAPACITY, THE PERSON ALLEGEDLY INJURED BY ETHYLENE OXIDE FROM WHOM THE CLAIM DERIVES, UNLESS OTHERWISE SPECIFIED.3
III.CLAIM INFORMATION
1.Have YOU suffered any physical injuries or illness as a result of YOUR alleged ethylene oxide exposure from the Willowbrook facility as described in III below?
Yes ☐ No ☐
If yes, please describe in detail the following:
a.The diagnosis or illness claimed and when any corresponding symptoms first began.
Special instructions: Please describe the nature and extent of the claimed diagnosis or injury with specificity. For example, for a cancer-related injury, it is important to write down the type and stage of cancer claimed. Similarly, if a miscarriage-related injury is claimed, please specify the number and type of miscarriage to the extent known.
_________________________________________
3 For example, if the Opt-Out is someone who has asserted a loss of consortium claim derived from injuries suffered by his spouse, Sections II-VI should contain information relating to the allegedly injured spouse.
b.When did YOU first receive a diagnosis, if any, of the injuries or illnesses or occurrences identified in II(1)(a) above? Please insert the month, day (if available), and year (MM/DD/YYYY) of diagnosis for each injury or illness claimed.
c.If YOU claim to have experienced symptoms prior date of diagnosis in part II(1)(a) above, please describe the symptoms and their dates of onset.
IV.EXPOSURE HISTORY
1. Identify any and all residences, places of employment, schools, or other locations where YOU were allegedly exposed to ethylene oxide from the Willowbrook facility, by name to the extent applicable (i.e., business or school), address, and dates of exposure (i.e., MM/DD/YYYY-MM/DD/YYYY).
a.
b.
c.
V.CURRENT MEDICAL CONDITION(S)
1.Do YOU currently suffer from any physical injuries, illnesses or disabilities other than those alleged to be the result of the Willowbrook facility’s ethylene oxide emissions identified in II(1)(a) above?
Yes ☐ No ☐
2.If yes, please list each injury(ies), illness, or disability:
VI.MEDICAL HISTORY
1.Please describe any other medical symptoms or conditions that YOU have experienced or been diagnosed with during the last 15 years, besides those alleged to be attributable to ethylene oxide exposure in Part II above. For each symptom or condition listed, please indicate the approximate date of onset and diagnosis.
VII.LOSS OF CONSORTIUM
1.Are you a Plaintiff who claims loss of consortium based on a family member who was allegedly injured by ethylene oxide exposure?
Yes ☐ No ☐
2.If yes, please describe each injury(ies), illness, or disability you claim to have suffered:
VIII.DECEASED INDIVIDUALS
1.Are you a Plaintiff and/or legal representative filling this out on behalf of an individual who is deceased?
Yes ☐ No ☐
If yes, please attach a copy of the Death Certificate and a copy of the letter of administration:
a Date of Death
b. Place of death (city, state and country)
IX.VERIFICATION
Under the penalties as provided by law pursuant to Section 1 -109 of the Illinois Code of Civil Procedure, the undersigned certifies that the statements set forth in this Plaintiff Fact Sheet are true and correct. This certification shall have the same effect as a verification provided and sworn under oath.
Date: __________________________
Signature_____________________________
Print Name____________________________
Willowbrook: Group Settlement Term Sheet Appendix F
INSTRUCTIONS: If your response to any question in the Mental Health Care Addendum exceeds the space limitation provided in these fillable PDF forms, you must attach additional pages labeling said pages as an Attachment to the respective document and identify the question to which the additional information applies to.
IN THE CIRCUIT COURT OF COOK COUNTY,
ILLINOIS COUNTY DEPARTMENT, LAW DIVISION
| | | | | |
IN RE: WILLOWBROOK ETHYLENE OXIDE LITIGATION |
Consolidated for Pretrial and Discovery Purposes Under No. 18 L 10475 |
Appendix F
MENTAL HEALTH CARE ADDENDUM TO PLAINTIFF FACT SHEET
This Mental Health Care Addendum (“Addendum”) must be completed by or on behalf of each Opt-Out, as defined in the Term Sheet, who has claimed on the Settlement Plaintiff Fact Sheet any psychological or psychiatric injury as a consequence of the Opt-Out’s alleged ethylene oxide exposure from the Willowbrook facility. The terms “psychological or psychiatric injury” and “psychological or psychiatric condition” include but are not limited to depressive disorders, anxiety disorders, and/or trauma- and stressor-related psychological or psychiatric disorders.
The terms YOU and YOUR below refer to the Opt Out, or, if the Opt Out is someone bringing a claim in a representative or derivative capacity, the person allegedly injured by ethylene oxide and from whom the claim derives.
I.CASE INFORMATION
1.Name of person on whose behalf this Addendum is being prepared (first, middle, last):
2.Name of person completing this form:
II.PSYCHOLOGICAL AND/OR PSYCHIATRIC INJURY(IES)
1.Please describe in detail the following:
a. Any psychological or psychiatric injury(ies) YOU claim are the consequence of YOUR alleged ethylene oxide exposure from the Willowbrook facility, date of onset of symptoms, and date of diagnosis.
b. Are the injuries identified in II(1)(a) above continuing?
Yes ☐ No ☐
If yes, please identify which injuries.
c. Did YOU ever suffer this injury(ies) prior to the dates set forth in the answer to II(1)(a) above?
Yes ☐ No ☐
If yes, when did YOU suffer the injury(ies) previously?
III.CURRENT PSYCHOLOGICAL OR PSYCHIATRIC CONDITIONS
1.Do YOU currently suffer from any diagnosed psychological or psychiatric conditions other than those that are the result of the Willowbrook facility’s ethylene oxide emissions identified in II(a)?
Yes ☐ No ☐
If yes, please state the following for each condition:
2.Identify the condition(s); their symptoms; date of onset; and date of diagnosis.
IV.MENTAL HEALTH HISTORY
1. Please describe any psychological or psychiatric conditions that YOU have previously experienced or been diagnosed with during the last 15 years, besides those alleged to be attributable to ethylene oxide exposure in Part II above. For each condition listed, please indicate the date of onset and diagnosis.
a.
b.
c.
d.
e.
V.VERIFICATION
Under the penalties as provided by law pursuant to Section 1 -109 of the Illinois Code of Civil Procedure, the undersigned certifies that the statements set forth in this Addendum are true and correct. This certification shall have the same effect as a verification provided and sworn under oath.
Date: __________________________
Signature_____________________________
Print Name____________________________
Willowbrook: Group Settlement Term Sheet Appendix G
| | | | | | | | |
| Case Name | Member Case Name | Plaintiff |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Harrell v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Adams, et al. v. Sterigenics, U.S., LLC, et al. | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Goodrich v. Sterigenics [Stayed] | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Horn v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Horn v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Horn v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Horn v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | DiCorpo v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | Horn v. Sterigenics | [***] |
| In re Sterigenics EtO Georgia | | [***] |
| Total Count | 31 | |
